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ABSTRACT 
 
 
NON-COVALENTLY FUNCTIONALIZED SWNTS AS 
POTENTIAL DELIVERY AGENTS FOR NOVEL BODIPY-
BASED PDT SENSITIZERS  
& 
THE DESIGN AND SYNTHESIS OF DENDRITIC LIGHT 
HARVESTERS 
 
 
Sündüs Erbaş 
M.S. in Materials Science and Nanotechnology 
Supervisor: Prof. Dr. Engin U. Akkaya 
August, 2009 
 
Photodynamic therapy (PDT) is a non-invasive method used for the treatment of 
a number of diseases including certain cancers and some cardiovascular 
diseases. Photodynamic action depends on absorbance of photosensitizer (PS) in 
near IR region of the spectrum and subsequent generation of cytotoxic singlet 
oxygen in the vicinity of the PS. Carbon nanotubes are widely used for 
biomedical applications due to their inertness, biocompatibility, cellular 
internalization, facile and multi-modification. We have synthesized and 
characterized novel water soluble boradiazaindacene (BODIPY)-based PS, non-
covalently attached on to the single wall carbon nanotube (SWNT). We have 
observed that near infrared absorbing photosensitizer preserve its singlet oxygen 
generation capability upon adsorption on SWNT. We have demonstrated that 
SWNTs can be used as the delivery vehicle of PS for the use in PDT. In the 
second part of this research, multichromatic cascade-type light harvesting 
BODIPY dendrimers were synthesized and highly efficient energy transfer was 
observed. Successful channeling of energy in a predefined region of the 
dendrimer was revealed. 
Keywords: Boradiazaindacene, photodynamic therapy, photosensitizer, single-
wall cabon nanotube, light harvesting, dendrimer 
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ÖZET 
 
 
YENĐ BODIPY-TEMELLĐ FOTODĐNAMĐK TERAPĐ 
SENSĐTĐZÖRÜ TAŞIMA AMAÇLI KOVALENT OLMAYAN 
SWNT TÜREVLENDĐRMESĐ  
& 
DENDRĐTĐK IŞIK HASADI SĐSTEMLERĐNĐN TASARIM VE 
SENTEZĐ 
 
 
Sündüs Erbaş 
Malzeme Bilimi ve Nanoteknoloji Programı, Yüksek Lisans 
Tez Yöneticisi: Prof. Dr. Engin U. Akkaya 
Ağustos, 2009 
 
Fotodinamik terapi, kanser ve kalp-damar rahatsızlıklarını da kapsayan birçok 
hastalığın tedavisinde kullanılan non-invazif bir tedavi yöntemidir. Fotodinamik 
etki, fotouyarıcının yakın kızılötesi bölgedeki ışığı soğurup mütakiben 
çevresinde sitotoksik singlet oksijen oluşturması prensibine dayanır. Karbon 
nanotüpler inert özellikleri, biyouyumlulukları, hücre içine alınabilmelerinin 
yanında kolay ve çeşitli modifikasyonlara açık olmaları sebebiyle biyomedikal 
uygulamalarda yaygınca kullanılmaktadır. Bu çalışmada, suda çözünür yeni 
BODIPY- temelli fotosensitizör tek-duvarlı karbon nanotübe (SWNT) bağlanıp 
karakterize edilmiştir. Yakın kızılötesi bölgede soğuran bu fotouyarıcının 
nanotübe bağlanma sonrasında singlet oksijen oluşturma kapasitesini koruduğu 
gözlenmiştir. Nanotüplerin fotodinamik terapide kullanılmak amacıyla 
fotouyarıcı taşınmasında kullanılabileceği bu çalışmayla gösterilmiştir. 
Çalışmanın ikinci kısmında, multikromatik şelale tipi enerji hasadı yapan 
BODIPY dendrimerleri sentezlenmiş, oldukça verimli enerji aktarımı 
gözlenmiştir. Enerjinin dendrimerin belirli bölgesine başarılı şekilde 
yönlendirilebileceği gösterilmiştir. 
Anahtar Kelimeler: Boradiazaindasen, fotodinamik terapi, fotosensitizör, tek-
duvarlı karbon nanotüp, enerji hasadı, dendrimer 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Photodynamic Therapy 
 
Photodynamic therapy is a relatively young, non-invasive approach to the 
treatment of certain diseases such as some malignant cancers, actinic keratoses, 
psoriasis, age-related macular degeneration, oesophageal diseases and some 
cardiovascular diseases.1 In this therapy, light-sensitive drugs (or 
photosensitizers) are introduced topically, intravenously or orally.1 After certain 
time of administration, usually 1 to 3 days, light of certain wavelength is 
exposed. This delay in light exposure maintains accumulation of photosensitizer 
(PS) in the region of interest up to 28:1 ratio of concentrations for tumor to 
normal tissue for some photosensitizers due to enhanced permeation and 
retention in tumor.2 Intracellular localization on the other hand, depends on 
hydrophobicity and charge of PS. Hydrophobic ones tend to localize in the 
membrane and cationic PDT agents are mainly accumulate in mitochondria.3  
Activation of photosensitizer using suitable light leads to formation of 
reactive oxygen species including singlet oxygen (O21) from molecular oxygen 
which attack to nearby molecules such as lipids, proteins or DNA, depending on 
the location of the photosensitizer and give oxidative damage to the 
corresponding biological structures.4,5 This in turn, results in cellular response 
such as initiation of apoptosis or necrosis, shut down of vascular supply which 
results in hypoxia or activation of immune system.6-8 The light used for PDT can 
come from either a laser or other sources such as light-emitting diodes (LEDs) 
and should be preferably red or near IR in color since light of this color 
penetrates through tissues better.9  
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1.1.1 History of Photodynamic Therapy  
 
Use of sun light for the treatment of certain diseases is not a recent finding, 
rather it was realized by Herodotes more than two thousand years ago and use of 
photoactive molecules for the treatment of vitiligo were described in holly book 
of India, Atharava-veda.10 The story of photodynamic therapy in scientific 
literature however, begins with Oscar Raab’s observation on toxic effects of 
acridine red molecule on certain bacteria in the presence of intense light.10-12 By 
doing control experiments, he proposed and demonstrated that presence of 
fluorophore is required for the corresponding light-induced toxicity. Scientists 
Tappeiner and Jesionek used the eosin dye for the treatment of skin cancer, thus, 
eosin becomes the first photosensitizer used for medical purposes.13  
Following these discoveries, in 1904, indispensable involvement of oxygen 
in the photodynamic response is realized by Tappeiner and Jodbauer.14 
However, exact mechanism of oxygen-dependent toxicity of photoactive 
molecules cannot be resolved until 1979, the year when electron spin resonance 
technique was used to monitor the generation of singlet oxygen, highly reactive 
excited state oxygen, by Moan et al.15  
First human trial of PDT was done by Meyer-Betz on himself and extreme 
apses and pain was observed.16 On the other hand, first clinical application of 
PDT was at Roswell Park Cancer Institute in 1978 by Dougherty et al.17 
Following this, in 1980 photofrin, a mixture of hematoporphyrin derivatives is 
approved by FDA as a photosensitizer. From that time on, a number of 
photosensitizers which are either porphyrin or haematoporphyrin derivative, 
such as HPPH, ALA, Levulan, Foscan, Metvix are approved by FDA or EU. 
Great success in treatment of a variety of diseases, mainly different forms of 
cancer is achieved. 
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1.1.2 Mechanism of Photodynamic Action 
 
Generation of tremendously reactive oxygen in its lowest lying excited state 
by means of photoactivation of fluorophore is the crucial step in the mechanism 
of this therapy. The steps involved in photon induced 1O2 generation are shown 
with a Jablonski diagram in Figure 1. Excitation of fluorophore via photon of 
appropriate energy from its ground state to the first excited state is the initiation 
step (step 1). From this singlet excited state, relaxation to ground state 
vibrational level of excited electronic state occurs. From here on, there are two 
possible pathways apart from radiationless relaxation to the ground state: 
electron can fall back to its electronic ground state which gives fluorescence 
(step 2) or it can go into an intersystem crossing to triplet excited state (step 4). 
If the latter pathway is favored, such as the case in the presence of heavy atoms, 
triplet excited state energy can be transferred to ground state oxygen to generate 
reactive singlet oxygen, otherwise phosphorescence, delayed fluorescence 
occurs when electron falls back to ground state of the photosensitizer (step 5).9,18  
 
Figure 1. Jablonski diagram of photosensitizer and oxygen 
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Biological outcome of photodynamic therapy basically relies on the 
reactivity of photogenerated singlet oxygen which either leads to the formation 
of other reactive oxygen species or directly gives oxidative damage to cell. Due 
to the short life time (0.6 µs) hence diffusion distance (0.1 µm) of singlet 
oxygen, oxidative damage to cellular structures is expected to be initiated in the 
vicinity of the photosensitizer.19 For the reasons mentioned above, localization 
of the photosensitizer determines the targets of reactive oxygen species and 
mode of cell death.  
 
1.1.2.1 Chemical Response; Oxidative Damage by 1O2 
 
Photosensitizer mediated cytotoxicity results from two different 
mechanisms. In type-I reaction, excited photosensitizer directly reacts with a 
substrate, namely a biomolecule and form unstable radicals. These radicals 
further react with other substrates or molecular oxygen to generate singlet 
oxygen. In type-II reaction, energy is directly transferred from excited PS to 
oxygen to produce 1O2. Generally, it is not easy to differentiate between these 
two modes and both reaction types are known to be involved in photodynamic 
action simultaneously.6  
Being a very powerful oxidant, 1O2 reacts immediately with a number of 
biomolecules giving rise to oxidative stress. Reaction with membrane lipids 
would be lipid peroxidation that alters membrane structure, integrity and 
fluidity. Decomposition of these peroxides produce lipid radicals, another 
cytotoxic danger   for the cell. Other reactive oxygen species generated by 1O2 
can attack free amino and thiol groups of amino acids and disrupt the folding 
and proper functioning of proteins.20 One reason of photoinduced increase in 
mitochondrial membrane permeability is thought to stem from the oxidation of 
disulfide histidine amino acids in membrane proteins, leading to formation of 
more labile membrane,  permits the passage of mitochondrial constituents, 
induce cell death consequently.21 Formation of different radicals and reactive 
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compounds in each step leads to the amplification of oxidative stress in the 
cell.22 In the structure of DNA, dioxyribose sugar and bases, especially thymines 
are prone to chemical attack by hydroxyl radicals that are generated by reactions 
of singlet oxygen.23 These type of modifications in DNA strand result in 
mutations; strand breaks. In addition, cross-linking of DNA with proteins or 
DNA itself is also observed as a genotoxic outcome of PDT.24 Singlet oxygen 
also impairs the normal functioning of DNA repair enzyme, thus, each damages 
on DNA accumulates and triggers cell death immediately after photodynamic 
action.25   
 
1.1.2.2 Biological Response 
 
Two modes of cell death, namely, apoptosis or necrosis can be induced in 
response to photodynamic therapy, each having different morphological 
properties.26 Apart from direct cytotoxic effect, photodynamic therapy results in 
shutdown of vascular supplements to the tumor tissue. Immunological 
stimulation against cancerous regions is a long term benefit of this type of 
therapy as opposed to most of the other types.27  
Apoptosis is programmed cell death characterized by DNA 
fragmentation, chromatin condensation and cell shrinkage. Molecular elements 
responsible for/having role in this phenomenon involve wide range of 
membrane and cytosolic proteins some of which are receptors or transporters. 
Mainly, apoptotic signals are introduced in two converging pathways: external 
signals are introduced to the cell through dead receptors initiated via ligand 
binding. This recruits some proteins to the receptor, induces the formation of 
death-inducing signaling complex, and activates certain caspases, cystein 
aspartic acid proteases such as caspase-8. Internal signals can also trigger 
caspase activation in response to release of cyctochrome-c and other 
mitochondrial apoptotic proteins. Formation of active protein complex from 
caspase-9, cytochrome-c, called apoptosome relays the apoptotic signal to entire 
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cell in an irreversible way, program cell death is implemented.19,28,29 Apoptosis 
in PDT can be triggered due to impairment of ion homeostasis and consequent 
increase in intracellular Ca+2 ion concentration. Drastic rise in Ca+2 ion 
concentration activates phospholipase C, protein kinase C, interferes with 
arachidonic acid metabolism all in turn lead to apoptosis and inflammatory 
responses.24  
 
Figure 2. Biological response induced by photodynamic therapy.19 
 
Another mode of cell death triggered by photodynamic therapy is 
necrosis, a more traumatic, unnatural death characterized by swelling of the cell, 
disruption of intracellular and plasma membranes and subsequent rupture of the 
cell, release the contents of the cytoplasm to the surrounding tissue. This type of 
cell death, together with apoptosis is the outcome of cytotoxic effect of 
photodynamic therapy.19  
Beside its cytotoxicity to the region of application, PDT has a very 
distinct property that is not found in traditional chemotherapy or radiotherapy, 
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immune system stimulation. Oxidative damage to the elements of cell 
membrane decreases the integrity and phospholipids are liberated. These 
phospholipids are rapidly metabolized to immune stimulatory molecules such as 
leukotrienes.24 When either apoptosis or necrosis takes place after photodynamic 
action, heat-shock protein-70 (HSP70) is induced.30 Being a chaperone protein, 
it interacts with tumor antigens, stimulate anti-tumor response and attract 
neutrophils to the side of tumor. Korbelik and Sun used this property of 
photodynamic therapy to develop cancer vaccines, namely, bio-sample that 
recognize and acts against tumor cells.31 For this purpose, they inject PDT-
applied cell lysates to mice, suffering from cancer. After a short time of 
administration, obvious regression in tumor size and healing was reported.  
 
1.1.3 Requirements for Photosensitizers 
 
The photosensitizer, which is introduced into the cells before light is shone 
onto the tissue, must have certain fundamental properties to make it suitably and 
successfully acting agent. Photodynamic action necessitates intrinsic ability of 
photosensitizer to generate reactive singlet oxygen species. Thus, specific 
molecules with appropriate chemical and physical properties are required such 
that the efficacy of singlet oxygen generation thus photodynamic action should 
be considerably high. 
Spin forbidden transition from triplet ground state of molecular oxygen to 
singlet excited state is enhanced with increased spin-orbit (SO) coupling since 
coupling of spin angular momentum with orbital angular momentum mix the 
singlet and triplet states such that triplet state has certain singlet character. This 
in turn, makes spin forbidden singlet-triplet transitions possible. Spin-orbit 
Hamiltonian term is proportional to fourth power of Z, presence of heavy atom 
increases spin-orbit coupling thus spin forbidden singlet-triplet radiationless 
transition. SO-Hamiltonian is formulated as below.32, 33  
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where e is electron charge, Z is atomic number, ao is Bohr’s radius, m is mass of 
electron, c is speed of light, n is principle quantum number, L and S are angular 
momentum and spin operators respectively. 
This phenomenon is studied experimentally in BODIPY dyes and it was 
verified by O’Shea et al. that presence of two bromine atom in the structure of 
molecule increases the efficacy of the photosensitizer up to thousand folds. 
Hence, photosensitizers having heavy atoms in their structures exhibit better 
singlet oxygen generation capability.  
Most photosensitizers degrade in the presence of light, so called 
photobleaching, mainly due to reactive oxygen species generated as a part of 
PDT action.35 For this reason, to maintain photodynamic character 
photosensitizers have to be photostable.  
 Due to the presence of absorbing molecules in the living organisms, 
tissue penetration depth of light at different wavelength differs considerably in 
different regions of the body. Certain aromatic compounds such as amino acids 
tyrosine, phenylalanine and tryptophan absorb near UV region, different regions 
of visible light are absorbed by melanin, collagens, nicotinamide, flavins, and 
haemoglobins. Beyond 1150 nm, light penetration decreases substantially due to 
absorbance of water. Considering the absorbance of these and other 
biomolecules, maximum penetration is achieved with light of the range 620-850 
nm, so called therapeutic or pharmaceutical window of the body. Thus, design 
or choice of photosensitizer should be accordingly in order to achieve sufficient 
intensity of light in the region of therapeutic action, it must absorb light within 
this given wavelength range strongly so that it can efficiently produce the 
reactive oxygen species.3, 9, 37 
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Figure 3. Therapeutic window of the body, absorbance of oxy-hemoglobin (HbO2), deoxy-
hemoglobin (Hb) and water.36 
 
Beside its photophysical properties already revealed, the sensitizer has 
other requirements for biological application such as biocompatibility. It should 
not have dark toxicity; in other words, has to be ineffective until light is exposed 
to it. In addition, an important necessity for practical medical use is that it 
should be water-soluble and there should be no immunological reaction against. 
 
1.1.3 Photosensitizers in Literature 
 
First generation PS are mainly porphyrin derivatives such as photofrin, 
hematoporphyrin which do not have strong absorption in the therapeutic 
window of the body.38 Phthalocyanine related sensitizers and synthetic chlorins 
are more promising when their absorptions are compared (Figure 4).38 
Xanthanes such as fluorescein, eosin and Rose Bengal are common singlet 
oxygen generating organic compounds.39 Perylenediimide dyes have high 
quantum yield and absorption maxima which can be shifted to longer 
wavelengths by proper modifications.39 The only drawback of this dye is its low 
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solubility in protic solvents.  BF2 chelated tetraaryl azadipyrromethene dyes 
(aza-BODIPY), as extensively studied by O’Shea et al, have sharp absorption in 
therapeutic window of the body and show highly efficient PDT character.34, 40  
Cyanine dyes, hypericin, squaraines, texaphyrins, fullerenes were also used as 
sensitizer.38, 39, 41 
 
Figure 4. Structures of some photosensitizers in literature. 
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Figure  5. BODIPY- based photosensitizers in literature. Compound 1 is the first BODIPY-
based photosensitizrs reported by Nagano et al., compound 2 and 3 were reported by Akkaya et 
al.42, 43, 44 
 
Recently, borondipyrromethene (BODIPY) dyes become attractive in this 
era when their high extinction coefficients and photostabilities are considered.42, 
43, 45
 Possibility of multiple and facile chemical modifications on this molecule 
allow  attachment of chemical groups that would enable selective tumor 
targeting, water solubility together with groups attached to increase 
photodynamic action (Figure 5).  
One impressive example of such BODIPY photosensitizer was synthesized 
by Akkaya et al.44 This photosensitizer, compound 3 contains chemical groups 
that detect the acidity and sodium concentration of the medium, namely, singlet 
oxygen generation property of the molecule is under the control of these two 
parameters (Figure 5 and Figure 6). Protonation of pyridine groups in acidic 
media causes a bathochromic shift in the absorbance. When light of 660 nm is 
introduced, only molecules with protonated pyridine groups are excited and 
show photodynamic action, provided photo-induced electron transfer (PET) is 
blocked by Na+ binding to crown ether moiety.  Thus, only in cancer tissues 
where sodium concentration is high and pH is low, 1O2 generation is 
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maintained.46, 47 Nagano et al. recently reported a BODIPY derivative that 
selectively inactivates protein after binding to its hydrophobic cavity.48  
 
Figure 6. Smart PS seeking for cancer parameters.44 
 
Nowadays, PDT with controlled generation of singlet oxygen is 
becoming more and more important. There are some recent examples in 
literature that rationally focus on this issue beside the Akkaya’s photosensitizer 
given above. One such example relies on Watson-Crick base pairing of DNA 
strands in which 5’ end of one strand is linked to the photosensitizer whereas 3’ 
end of complementary strand hold a quencher.49 When there is no quencher-free 
complementary strand, ability of photosensitizer to generate singlet oxygen is 
abolished due to the presence of quencher in close proximity to enable Förster 
resonance energy transfer (FRET, through space) from PS to quencher.50-52 
However, in the presence of a number of target-DNA around, statistically, the 
chance of pairing with quencher-free DNA increases which in turn increases the 
singlet oxygen mediated toxicity. This type of dual system where outcome is 
dependent of hybridization or proximity is called molecular beacon.53 
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Figure 7. Cancer selective activation of PS through release of quencher by protease 
MMP7.54 
 
One other molecular beacon designed to control photodynamic action is 
published by Zheng et al. and Tung et al. separately, and depends on cancer 
specific expression of proteases (Figure 7).54, 55 In the case of Zheng’s research, 
photosensitizer is chemically linked to a quencher molecule called Black Hole 
Quencher 3 through specific peptide spacer. This spacer has special amino acid 
sequence, the sequence specifically recognized and cleaved by matrix 
metalloproteinase-7, MMP7. This enzyme is known to be over expressed in 
certain cancer types such as colon, pancreas and breast cancers, hence, quencher 
free photosensitizer is ready to generate cytotoxic agents only in these specific 
tissues.54, 56  
 
Figure 8. Controlled photodynamic action based on quenching ability of SWNT.57 
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The example shown in Figure 8, based on the quenching of the 
photosensitizer, chlorine-e6 when it comes close to the surface of single walled 
carbon nanotube (SWNT).57 An aptamer attached to the photosensitizer favors 
this interaction. However, when aptamer preferentially binds to the target, PDT 
agent detaches from the SWNT, gains its ability to generate singlet oxygen. 
Thus, the ability to generate singlet oxygen is maintained only in the presence of 
target molecule. 
 
1.1.5 Clinical Applications 
 
 Starting with the first promising medical trial in 1970s photodynamic 
therapy is widely used in a number of diseases. Most of the photosensitizers 
approved so far and the diseases they are used for are listed in Table 1. 
Considering the exigency of conveying light to the region of treatment, 
dermatologic applications became the first type of trials. In these first 
treatments, nearly all primary skin cancers such as basal cell carcinomas showed 
complete response whereas secondary cancers that are formed as a result of 
breast, colon or endometrium cancers, 80% response were reported.58  
 Age-related macular degeneration is an ophthalmic disease to which PDT 
is applied. A photosensitizer called Verteporfin is approved as a PDT agent and 
placebo controlled trials demonstrated that the treatment maintains a stabilized 
vision afterwards.59 One other ocular use of PDT was in treatment of choroidal 
hemangiom, in other words eye cancer. It has been shown in a 10-case study 
that PDT results in regression of the tumor and reduction in the vascular 
structures.60 
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Table 1. Some PSs approved so far and the diseases they are used for.38 
 
Photosensitizer Trade 
Name 
Approval λ(nm) Area of Use 
Porfimer sodium Photofrin 1998  
FDA 
630 Lung, Barrett’s 
esophagus 
ALA-PpIX Levulan 
Keratastick 
1999 
FDA 
405 
635 
Actinic Keratosis 
Methyl 
aminolevulate-PpIX 
Metvix 2004 
FDA 
405 
635 
Actinic keratosis 
Hexyl aminolevulate-
PpIX 
Hexvix 2005 
EU 
405 Detection of 
bladder tumors 
BPD-MA Verteporfin, 
Visudyne 
2000 
FDA 
689 Choroidal 
neovascularization 
mTHPC Foscan 2001 
EU 
652 Head and neck, 
prostate, pancreas, 
esophagus, 
mesothelioma 
Motexafin Lutetium MLu, Lutex, 
Lutrin 
Phase I 732 Prostate, 
atherosclerosis 
Pd-
bacteriopheophorbide 
Tookad Phase I 762 Prostate 
Taloporfin sodium LS11 Phase 
I&II 
664 Choroidal 
neovascularization, 
liver and colorectal 
metastasis 
Silicon 
pthalocyanine-4 
PC-4 Phase I 672 Skin 
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  In head and neck cancers, those of cancers develop in oral cavity, the 
pharynx, the nasal cavity and larynx, PDT is preferred as opposed to other 
conventional radiotherapy and chemotherapy because of higher cure rates and 
better cosmetic outcome.61 Photosensitizers, photofrin and foscan are approved 
to be used in this type of applications. Treating brain tumors with other common 
surgical methods is challenging due to the risk of giving damage to nearby 
essentially important structures. That is the reason why PDT is used as a post-
surgical follow-up procedure for these types of cancers. In late 1990s, Stummer 
et al. were succeeded in complete removal of tumor in malignant glioma 
tissue.62 Complete recovery of visual field, a 46% reduction in tumor size in 
pituitary adenomas within two years is also reported.63 
 Animal trials and small group patient trials in some cardiovascular diseases 
such as atherosclerotic plaque, hyperplasia, restenosis and cancers such as 
gastroenterological, mesothelial and gynecological cancers also give very 
promising results.64 It can be said that PDT can be used in the treatment of these 
diseases as well in the near future.  
 
1.2 Carbon Nanotubes 
 
Carbon nanotubes (CNT) are one dimensional cylinderical allotropes of 
carbon which are formed by rolling of single or many sheets of graphite with a 
diameter of a few nanometers. The one with single layer is called single-wall 
carbon nanotube (SWNT) and those with multiple layers are called multi-wall 
carbon nanotube (MWNT). First discovered by Iijima et al. carbon nanotubes 
attract enourmous attention as nanomaterial because of their unique electronic, 
mechanical and structural properties.65, 66 Because of its high electron 
conductivity, it is used to develop molecular electronic devices and their use in 
biomedical area is increasing.66-68 Carbon nanotubes can be functionalized to 
modify electronic properties or to make them better delivery system for drugs or 
related therapeutic agents.  
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1.2.1 Modifications of Carbon Nanotubes 
 
Although CNTs are very promising for a number of research and 
application, they suffer from severe solubility problem such that they 
immediately form bundles and aggregates through strong van der Waals 
interaction between the side walls.69 This drawback can be handled via covalent 
or non-covalent functionalization of CNTs which interfere with bundle 
formation and increase solubility. In order to preserve electronic properties by 
maintaining sp2 hybridization of carbons and for the simplicity of procedure 
non-covalent modifications are preferred.  
 
           Figure 9. Modifications of carbon nanotubes.70 
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1.2.1.1 Covalent Modifications of Carbon Nanotubes 
 
Covalent modification of carbon nanotubes is quite difficult due to lack 
of solubility in any kind of solvent. On the other hand, it is possible to oxidize 
ends of CNTs to carboxylic acid by means of refluxing in concentrated nitric 
acid.71-73 This procedure also induces defects on the walls of CNTs which 
affects their electronic properties but not a concern for most of the biomedical 
applications.74 Carboxylic acid bearing CNTs can be further modified using 
well-known chemical methods to increase their solubility and to functionalize 
for specific use. Besides, having higher curvature, thus strain, CNTs possess 
greater reactivity compared to flat graphene sheets.75 This strain-dependent 
partial reactivity allows chemical functionalization on the side walls of CNTs 
through nitrene addition, hydrogenation, arylation, 1, 3-dipolar cycloaddition, 
fluorination or alkylation.76-84 
 
1.2.1.2 Non-covalent Modifications of Carbon Nanotubes 
 
Modification of CNTs without any change in their structure or 
electromechanical properties are feasible through non-covalent modification 
which can be done either through hydrophobic interactions of surfactants or 
through wrapping of polymers, DNA on the walls of CNTs.85-89 In addition, a 
number of aromatic compounds adhere on the side walls of CNTs through pi-
stacking interactions (Figure 9).70 Among such compounds, interaction of 
pyrene with CNTs was well studied.90, 91 The stability against desorption make 
pyrene-CNT complex very promising for biomedical applications as well as 
molecular electronics. Interaction of pyrene with CNTs can be easily 
characterized using quenching of pyrene emission.92, 93  
Apart from pyrene, other conjugated molecules also bind to the wall of 
CNTs through pi-stacking such as perylene, porphyrin, Congo red dye, trypan 
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blue dye.94-96 The main advantage of non-covalent modifications is the lack of 
requirement of harsh conditions as in the case of most of chemical 
modifications. Simple sonication is enough for adherence of polymers or 
aromatic moieties on the walls of CNTs.85-96  
 
1.2.2 Biomedical Applications  
 
Carbon nanotubes are appropriate tool for biomedical applications because 
of their facile internalization into cells.97 Besides, no significant toxicity was 
reported although a number of researches were done on this subject.98-104 CNTs 
are mainly used as delivery vehicle for proteins, nucleic acids for therapeutic 
purposes or certain radio-labeled moieties and fluorescent molecules for 
imaging purposes.68 Interesting researches where CNTs were used as substrate 
for neurons, was also done where differently functionalized CNTs induce 
different branching as the neurons grow.105 Carbon nanotubes carrying different 
anticancer drugs and photodynamic therapy reagents are also reported by 
others.57, 106, 107 
 
1.2.2.1 Biodistribution and Cytotoxicity 
 
Biomedical use of carbon nanotubes became more and more popular 
within last ten years due to its facile preparation as delivery systems. In order to 
be used as a real delivery system or a biomedical tool for other bioapplications, 
toxicity, biocompatibility and possible interference with biochemical and 
cellular functions have to be investigated extensively. For this concern, a 
number of researches were done either to determine the distribution of CNTs 
throughout the body, retention, excretion or possible pathological response 
induced within the organisms.  
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In an attempt to determine biocompatibility and cytotoxicity Ausman et 
al. prepared different water-dispersible SWNTs and examined the role of degree 
of functionalization of SWNT for biocompatibility in human dermal fibroblast 
cell culture.98 As a consequence, use of solubilized nanotubes rather than naked 
ones are recommended in order to prevent toxicity. Further, Dumortier, Prato 
and Bianco et al. reported that solubilized carbon nanotubes do not abolish cell 
viability nor interfere with proper functioning of primary immune cells.99  
 
Figure 10. Biodistribution and rapid clearance of carbon nanotubes.100 
 
Biodistribution of CNTs and clearance rate from the body of the mice 
were examined in two different studies and consistent results were obtained.100, 
101
 Although CNTs were accumulated in certain parts such as kidney and muscle 
right after administration, they are cleared rapidly within a few hours and 
excreted through feces or urine (Figure 10).100 Circulation half life of CNTs was 
determined to be 3.5 hours and 5.5 hours for diethylenetriamine pentaacetic acid 
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and glucoseamine functionalized CNTs respectively. When long term pathologic 
effects of CNTs are considered, no sufficient experiments are done yet, except 
from a few pilot researches. In one such research CNTs injected into the 
abdominal cavity of mice cause asbestos-like symptoms such as inflammation 
and lesion.102 Dose dependent inflammation in lung was observed in a 3 months 
research on rat.103 However, in a different study mice were observed for much 
longer time, 4 months after intravenous injection of polyethylene glycol 
functionalized CNTs and no significant pathogenicity was observed.104 These 
works again confirms that CNTs toxicity is associated with its degree of 
functionalization and highly soluble CNTs are required to avoid possible side 
effects.   
 
1.2.2.2 SWNT as Delivery System 
 
Considering delivery systems, the most important problem for bio-
application is their internalization by cells. They require additional specific 
functionalization to facilite entrance into the cell. CNTs, on the other hand, are 
shown to be internalized into mammalian cells mainly through energy 
dependent mechanism, endocytosis.97, 108, 109 Moreover, by providing cell 
specific targeting groups CNTs can more selectively accumulate in certain 
tissues such as the case in the work of Dai et al.110 In this study, SWNTs 
carrying RGD amino acids, cancer specific integrin αβ antagonist, were 
prepared and the distribution of nanotubes was monitored through positron 
emitting 64Cu. Biological imaging using fluorophore-CNT conjugates were also 
done.111 Antibody conjugated non-covalently modified SWNTs were used as 
electronic biosensors through which disease specific biomolecules can be 
detected.112  
Carbon nanotubes absorb near-infrared light, using this property, thermal 
destruction of cancer cells were achieved.113-115 In another research, controlled 
release and subsequent activation of photosensitizer in the presence of tumor 
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markers was studied (Figure 8).57 In this research, SWNT inhibit the singlet 
oxygen generating capability of the photosensitizer until tumor marker is 
present. More interestingly, Dai et al. non-covalently functionalized SWNTs 
using hydrophobic interaction of phospholipids with SWNT wall; small 
interference RNA (siRNA) was attached to phospholipids via disulfide 
linkage.116, 117 Reduction of disulfide bond to thiol released siRNA and 
successful gene silencing was observed.  
 
Figure 11. Targeted delivery of cancer drug using SWNT as delivery vehicle.118 
 
Three different anticancer drug-loaded CNTs were rationally designed and 
delivered by two different groups. Dai and Lippard et al. tethered Pt (IV) 
complex on SWNT and release of toxic cis-[Pt(NH3)2Cl2] upon intracellular 
reduction induced tumor cell death.106 Low pH in cancer cells facilitate the 
reduction, thus release of active anticancer complex and there is an obvious 
increase in cytotoxicity of SWNT-drug conjugate compared to free drug. Same 
drug was used recently by other research group, where additionally epidermal 
growth factor (EGF) was attached to SWNTs to maintain cancer targeting 
(Figure 11).118 EGF conjugated, drug loaded SWNTs were internalized by 
cancer cells whereas cells having reduced expression of EGF receptor (EGFR) 
failed to internalize the SWNTs. In the research of Wong and Ojima et al. well-
known microtubule destabilizing anticancer drug taxoid was covalently attached 
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on the surface of the SWNT through disulfide bond.107 Gluthathione (GSH) 
mediated reduction of this bond in specific tissue liberates the drug and induces 
cell death in the vicinity (Figure 12). 
 
Figure 12. Gluthathione mediated drug delivery using SWNT as a delivery vehicle.107 
 
Taking their biocompatibility, non-toxic character into account and 
considering all the examples given above, SWNTs seem to be very promising 
delivery system and material for other biomedical applications.  
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1.3 Light Harvesting and Energy Transfer 
 
1.3.1 Energy Transfer Mechanisms 
 
Energy transfer is the process where energy is transmitted from a 
chromophore in its excited state to a different chromophore in its ground 
state.119 Excitation energy of the former, donor (D) is used to excite the latter, 
the acceptor (A) to its first singlet excited state. Energy transfer can be 
characterized using different approaches; comparing relative lifetimes, quantum 
yields, quenching of the donor emission or increase in acceptor emission would 
be parameters to follow. Energy transfer is affected from rate of other 
deactivation pathways of excited system, thus chromophores have to be suitable 
to compete with these pathways.119-120 Lifetime of excited state has to be longer 
than time required for energy transfer. There are two different types of energy 
transfer mechanisms called Förster and Dexter types, which are theoretically 
well established and experimentally verified.  
 
Figure 13. Schematic illustration of Förster and Dexter types of energy transfer. 
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1.3.1.1 Dexter Type Energy Transfer 
 
Dexter Type, also called “through bond”, energy transfer basically relies 
on orbital interaction of donor and acceptor molecules leading to exchange of 
electrons from the highest occupied level of the donor to the lowest unoccupied 
level of the acceptor.121 Simultaneous exchange of ground state electrons 
accompanies this process (Figure 13).119 This dependency on orbital interaction 
restricts energy transfer to very short distances, usually less than 10 Å.120 As a 
consequence, energy transfer rate constant decreases exponentially with 
increasing donor-acceptor separation as formulated below.  
                         kET = K J exp(-2RDA / L)                       (2) 
where K represents orbital interaction, J is the overlap integral between donor 
emission and acceptor absorbance, RDA is the donor acceptor separation and 
finally L is the van der Waals radii.120  
Dexter type energy transfer systems were designed and synthesized with 
different molecules as shown in Figure 14. These Dexter systems exhibit energy 
transfer upon excitation at donor’s absorbance wavelength in each system. In 
porphyrin-based system (Figure 14A) central porphyrin was decorated with four 
terminal pophyrins coordinated to zinc.122 This difference in the structure allows 
energy transfer from the terminal porphyrins to the center through ethynyl 
bridge. In anthracene-BODIPY system as shown in Figure-14B, very fast energy 
transfer (~200 fs) from anthracene to BODIPY was observed upon excitation at 
anthracene’s absorbance wavelength which would be due to parallel alignment 
of S1 - So transition dipole moments of donor and acceptor respectively.45,123  
One interesting example of Dexter type energy transfer in literature 
would be the one shown in Figure 14C. These ligand-metal based systems 
provide unidirectional energy transfer in a linear array of system which would 
be used in the production of molecular wires.124 In this primitive example, 
efficient energy transfer from Ru and Os complexes to anthracene was observed.  
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Figure 14. Some Dexter type energy transfer systems in literature.122-124 
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1.3.1.2 Förster Type Energy Transfer 
 
 In contrast to Dexter type, Förster resonance energy transfer (FRET) or 
through space energy transfer does not depend on orbital interaction, hence, 
larger separation between donor-acceptor still would be allowed to achieve 
energy transfer. Spectral overlap between donor emission and acceptor 
absorbance is essentially important together with relative orientation of 
transition dipoles of donor and acceptor.50,51,125 Considering the fact that, energy 
is not transferred through bond, rather through space; other deactivation 
processes affect the efficiency of energy transfer. Deactivation would be due to 
intrinsic photophysical properties of chromophores such as internal conversion 
through vibrational relaxation, quantum yield of donor or as a result of solvent 
refractive properties.120 The distance between donor and acceptor at which half 
of the excited donor energy is transferred to the acceptor is called Förster 
distance (Ro) and formulated together with energy transfer rate constant (kFRET) 
as shown below:  
   Ro = 9.78 x 103 [κ2 n-4 QD J(λ) ]               (3) 
 
kFRET = [ 900 (ln10) κ2 ΦD J(λ) ] / [128 pi5 n 4 N τD R6DA ]   (4) 
 
where κ represents relative dipole moment orientation of excited donor and 
ground state acceptor, n is the refractive index of the medium, QD is the 
quantum yield of the donor in the absence of acceptor, J(λ) is spectral overlap 
integral of donor emission and acceptor absorbance, τD is excited state lifetime 
of donor in the absence of the acceptor chromophore and finally RDA is donor-
acceptor separation.120  
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1.3.1.2.1 Determination of FRET Efficiency  
 
 FRET efficiency can be determined in a number of ways; in general, 
there are two different approaches, steady state and time-resolved.126 In one of 
the steady state approach, decrease in donor fluorescence quantum yield is used. 
However, in this method one should be careful to avoid so called inner filter 
effect which refers to reabsorption of the emitted light by the same molecule or 
other unexpected ones. Self quenching problem can be solved using very dilute 
solutions.127-128 In this method, energy transfer efficiency is formulated as 
shown below:  
     E = 1 - ΦDA / ΦD          (5) 
where ΦDA and ΦD  are quantum yield of donor in the presence and absence of 
acceptor respectively. Excitation spectra or enhancement in fluorescence 
emission of the acceptor can be used to determine energy transfer in steady state 
approach. Corresponding equation is given below:  
 
          E = AA (λD) / AD (λD) * [IAD(λAem) / IA(λAem) - 1]           (6) 
 
where AA  and AD refers to absorbance values of acceptor and donor ar the 
maximum absorbance wavelength of donor. IAD and IA refer to integrated 
emission area of acceptor in the presence and absence of donor at λAem 
respectively.  
 Time resolved approach provides more accurate results since inner filter 
effect or errors associated with integration are lacking here.  This method is 
based on time-resolved emission of any of acceptor or donor. If the decay of 
fluorescence is single exponential, FRET rate constant and FRET efficiencies 
can be defined as shown below:126, 129 
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    kFRET = 1/τDA-1/τD        (7)
    
 
      E = 
  
τD  kFRET/(1+τDkFRET)                                      (8) 
 
where τD and τDA refer to excited state decay time (lifetime) of donor in the 
absence and presence of acceptor respectively. More simply, FRET efficiency 
can be found using following equation:  
 
          E = 1 - τDA/τD       (9)
    
 
 
1.3.1.2.2 Examples of FRET Systems in Literature 
 
 BODIPY dyes are widely used in energy transfer systems some of which 
are shown in Figures 15 and 16. In the example shown in Figure 15, four 
BODIPYs were attached covalently to perylene diimide core. In accordance 
with the increase in BODIPY number on the structure, extinction coefficient of 
the molecule at BODIPY’s maximum absorbance wavelength (526 nm) 
increases dramatically to 250000 M-1cm-1.130 Energy transfer efficiency was 
determined to be 99% with a critical Förster radius of 4.7 nm. In the second 
example shown in Figure 15, enhancement in emission of the core distyryl-
BODIPY was observed as the number of terminal BODIPY donors was 
increased in number, as expected.131  
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Figure 15.  Some BODIPY-based Förster type energy transfer systems130-131 
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Figure 16. pH-controlled FRET.132 
 
 One interesting example of FRET was shown in Figure 16 where donor 
and acceptor distance depends on the pH of the media. In acidic conditions, 
FRET is abolished and donor emission was observed at 542 nm.132 In this case, 
the whole molecule is extended such that the distance between donor and 
acceptor is 7 nm. On the other hand in the contracted form, the distance 
decreases almost ten folds, thus, energy transfer is observed. Change in FRET 
efficiency upon conformational transformation is extensively used in protein 
labeling and enzyme dynamics.  
 Apart from conformational change analysis, FRET systems are used to 
construct chemical or biological sensors, to determine ligand-receptor 
interaction, membrane organization assays, to monitor hybridization of nucleic 
acids and  a number of other applications.126 
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1.3.2 Light Harvesting 
 
Scientists usually admire the biological mechanisms which are shaped 
through millions of years of optimization processes to yield a system, perfectly 
tuned to work efficiently under the rules of earth. Photosynthesis is one such 
marvelous system in organisms that is evolved to convert sun light into chemical 
energy in the form of adenosine triphosphate (ATP).133 Architectural design and 
synergistic functionality of elements of this energy conversion complex is 
inspired, hence, researches try to mimic certain parts of this system for a variety 
of purposes such as frequency conversion, signal amplification, artificial 
photosynthetic systems, dye-sensitized solar energy and molecular 
optoelectronic applications.134-137 
 Light harvesting (antenna) complex simply means array of different 
chromophores with different but mutual spectral properties interacting 
photophysically to funnel energy in certain part of the complex.138 X-ray 
crystallographic structure and functionality of antenna complex in purple 
bacteria were well-studied and a number of artificial systems were designed and 
synthesized.139 
 
1.3.2.1 Light Harvesting in Purple Bacteria 
 
 In purple bacteria, extensive study on light harvesting complex and 
subsequent redox reactions were done. Femtosecond energy transfer between 
units allows channeling of light energy to the core structure called reaction 
center. This reaction center initiates the redox processes leading to generation of 
proton gradient and release of oxygen at the end.140 
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Figure 17. Antenna system in purple bacteria.141 
 
Antenna system in purple bacteria composed of approximately 
250 chlorophyll (BChl a) pigments and carotenoids having slightly different 
spectroscopic properties.141 As shown in Figures 17 and 18, energy is transferred 
from outer LH-III comlex to the inner reaction center. Hopping energy is either 
within the complex (dashed lines) or between different complexes (solid line) as 
shown in Figure 18. Although most purple bacteria have LH-I, LH-II complexes 
and reaction center, not all have LH-III complex.141  
 
 
 
Figure 18. Energy levels of photosynthetic elements in purple bacteria.141 
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 Within the LH-II complex, there are two different chlorophylls absorbing 
at 800 and 850 nm (B800 and B850 respectively). Rapid energy transfer from 
B850 (green) to B800 (blue) within 700 fs occurs.140-141 In all complexes, 
carotenoids contribute to harvesting by transferring its energy to exciton states 
of the B850 with 100% efficiency. These exciton states are formed as a result of 
interaction of intimately arranged chlorophylls. Both Dexter and Förster type 
mechanisms are involved in whole light harvesting processes.141  
 
1.3.2.2 Artificial Antenna Systems 
 
 Artificial antenna complexes that resemble biological counterparts in 
organization and light harvesting were published. These systems mimic the 
circular arrangement of pigments in LH-II complex of purple bacteria. One such 
example is shown in Figure 19, twelve porphyrins are assembled noncovalently 
to form circular array where maximum separation, namely radius of antenna is 
4.1 nm.142 
 
Figure 19. Artificial antenna in the form of slipped-cofacial array of chromophores.142 
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In this synthetic system, no protein matrix assistance is required as in the case of 
biological antenna since chromophores readily self-arrange through coordination 
of imidazolyl to Zn at the core of porphyrin to form perfect circular geometry. 
Thus, in this example “slipped-cofacial” placement which is crucial in the 
accomplishment of antenna is mimicked.142  
 
Figure 20. Artificial antenna and reaction center.143 
 
 One very exciting work was published by Tkachenko and D’Souza et al. 
and shown in Figure 20.143 Primitive but entire mimicry of photosynthetic 
system was constructed with an energy donor BODIPY, acceptor Zn-porphyrin 
two of which resembles antenna part of biological counterpart and finally an 
electron acceptor fullerene self-assembled to other part. Fullerene corresponds 
to reaction center, accepts electron from Zn-porphyrin and charge separation 
persists quite long time.143 
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1.3.2.3 Light Harvesting Dendrimers 
 
From their first synthesis on, dendrimers with branched construction are 
a focus for a variety of research due to their rational and versatile structure. 
Since proximity of donor-acceptor affects efficiency of energy transfer 
exponentially in Dexter type and sixth power of distance in Förster type, 
appropriate placement of chromophores in light harvesting systems is 
essential.126 Hence, dendritic architecture provides a suitable scaffold for this 
type of systems by enabling arrangement in an array of spectral overlap. Further, 
it was postulated that energy dissipation due to collisions are diminished in 
dendritic scaffolds.138 
 First dendritic type energy transfer system was published by Balzani et 
al. in 1992 which was composed of complexes of Ruthenium and Osmium.144-145 
Following this, first unidirectional energy transfer from the phenyl acetylene 
outer units to perylene core was reported by Xu and Moore et al.146 Dendritic 
benzyl ether ligands coordinated to core lanthanide was also observed to 
enhance core luminescence as reported by others.147 In addition, a number of 
pophyrin-based dendritic antennas were synthesized and their photophysical 
properties were studied.148-149  
 Frechet et al. synthesized an antenna that consists of multiple 
chromophores with regular arrangement (Figure 21).150 At the heart of the 
antenna, there lies perylene dye (λabs = 555 nm) as final acceptor. This core was 
decorated with four fluorol 7GA (λabs = 415 nm, λem = 520 nm). At the outer 
shell of the dendrimer eight Coumarin 2 donors are present (λabs = 350 nm, λem 
= 440 nm). Suitable spectral overlap and distance between donor-acceptor 
conjugates allows successful energy transfer in a cascade system from the 
terminal to the center. Förster resonance energy transfer efficiencies are very 
high even between coumarin 2 and perylene units which have smallest spectral 
overlap.150  
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Figure 21. Cascade energy transfer in multichromatic antenna150 
 
 In conclusion, dendritic light harvesting systems allow proper 
arrangement of spectrally mutual chromophores in close proximity and enables 
unidirectional energy transfer to the core chromophore.  Large complex of 
biological counterpart can be effectively constructed with this kind of chemical 
approach. 
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CHAPTER 2 
 
EXPERIMENTAL PROCEDURES 
 
 
2.1 General 
 
All chemicals and solvents purchased from Sigma-Aldrich were used 
without further purification. 1-2 nm X 500 nm SWNT was purchased from 
Aldrich (catalog no: 652512). PEG-N3 was synthesized according to 
literature.151Spectra of 1H NMR and 13C NMR were recorded using a Bruker 
DPX-400 in CDCl3 with TMS as internal reference. Splittings in the spectra are 
shown as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), p (pentet), 
dt (doublet of triplet), and br (broad). 
Absorption spectrometry was performed using a Varian spectrophotometer. 
Steady state fluorescence measurements were conducted using a Varian Eclipse 
spectrofluorometer. Column chromatography of all products was performed 
using Merck Silica Gel 60 (particle size: 0.040–0.063 mm, 230–400 mesh 
ASTM). Reactions were monitored by thin layer chromatography using 
fluorescent coated aluminum sheets. Solvents used for spectroscopy experiments 
were spectrophotometric grade. Mass spectrometry measurements were done at 
the Ohio State University Mass Spectrometry and Proteomics Facility, Ohio, 
U.S.A.  
AFM images were acquired in UNAM, Ankara, using PSIA XE-100E AFM 
and Multi75AI AFM tip. TEM images were aquired in UNAM, Ankara, using 
FEI Technai G2 F30 high resolution transmission electron microscope and 
carbon grid.  
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 Quantum yield measurements and calculations were done using 
Rhodamine G6 (excitation 488 nm, water), Sulforhodamine 101(excitation 550 
nm, ethanol) and Cresyl Violet (excitation 610 nm, methanol) as standard 
chromophores having quantum yields 0.95, 0.90 and 0.66 respectively. All 
absorbance values were below 0.1 to avoid self quenching. Following formula 
was used for calculations: 127 
 
                Q = QR (I/IR)*(AR/A)*(n2/nR2)    (6) 
 
where QR stands for quantum yield of reference, I and IR for integrated area of 
emission spectrum for specific wavelength for sample and for standard 
respectively, A and AR represents absorbance of corresponding wavelength for 
sample and standard, n and nR refer to refractive indices of solvents in which 
sample and standard compounds were dissolved respectively.  Refractive index 
values were taken to be 1.333 for water, 1.3624 for ethanol and 1.329 for 
methanol. All samples except standards were dissolved in chloroform which has 
an n value of 1.49.  
 Lifetime measurements were done at Photon Technology International 
(Canada) Inc. Fast Kinetic Application Laboratories, Ontario Canada. The 
measurements were carried out with the TM-3 LaserStrobe time-resolved 
fluorometer from PTI utilizing a pulsed nitrogen/dye laser excitation and the 
stroboscopic detection system. The dye laser excitation was at 526, 590 and 653 
nm. The instrument response function was measured with an aqueous Ludox 
solution.  The decays were analyzed with a multiexponential fitting function by 
iterative reconvolution and chi-square minimization. Fluorescence decay results 
were given in Appendix C.  
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2.2 Experimental Part-I 
 
2.2.1 Design of Photosensitizer 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. (a) Structure of target PS, compound 1, (b) 3D structure of compound 1 on SWNT 
 
As shown in Figure 22, BODIPY-based compound 1 is designed as 
photosensitizer in this research. Iodines are attached to enhance intersystem 
crossing, thus provide spin forbidden singlet-triplet transition. PEG is attached 
through triazole ring to make the photosensitizer water solubility. Presence of 
pyrenes enables SWNT attachment.  
(A) 
(B) 
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2.2.2 Synthesis of Photosensitizer 
 
2.2.2.1 Synthesis of 4-(8-chlorooctyloxy)benzaldehyde (3) 
 
Figure 23. Synthesis of compound 3 
 
1,4-hydroxybenzaldehyde (1.25 g, 10 mmol) and 1,8 dichlorooctane 
(2.75 g, 15 mmol) were dissolved in acetonitrile (100 ml). K2CO3 (2.76 g, 20 
mmol) and a few crystals of 18-crown-6 were added. The reaction mixture was 
refluxed for 16h. Then, acetonitrile was evaporated in vacuo and extracted with 
water and chloroform. Organic layer as dried with Na2SO4 and evaporated in 
vacuo. The product was purified by silica gel column chromatography using 
CHCl3/Hexane (80:20, v/v). Fraction containing compound  3 was collected 
then the solvent was removed under reduced pressure (3 mmol, 806 mg, 30% ). 
  
1H NMR (CDCl3, 400 MHz, δ ppm) 1.30-1.52 (m, 8H), 1.72-1.89 (m, 4H), 3.54 
(t, J= 6.7 Hz, 2H),  4.05 (t, J= 6.5 Hz, 2H), 6. 98 (d, J= 8.76 Hz, 2H), 7.83 (d, J= 
8.8 Hz, 2H), 9.89 (s, 1H) 
13C NMR (CDCl3, 100 MHz, δ ppm) 22.85, 26.76, 28.76, 29.00, 29.13, 32.56, 
45.08, 68.33, 114.74, 131.97, 164.22, 190.78. 
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HRMS-ESI: calculated for [M+H] 269.1308, found 269.1303, ∆= 1.9 ppm  
 
2.2.2.2 Synthesis of 4-(8-(pyren-1-ylmethoxy)octyloxy) benzaldehyde (4) 
 
Figure 24. Synthesis of Compound 4 
 
Pyrenyl methanol (696.84 mg, 3 mmol) was dissolved in DMF (5 ml).  
120 mg 60% NaH was added slowly and the reaction mixture was stirred at 
room temperature for 20 min. 1,8-dichlorooctane 3 dissolved in DMF (5 ml) and 
added into the previous solution. After 20h of reflux, it was extracted with 
saturated NaHCO3 aqueous solution and CHCl3, organic layer was dried with 
Na2SO4 and evaporated  under reduced pressure. The product was purified by 
silica gel column chromatography using CHCl3/Hexane (75:25, v/v). Fraction 
containing compound 4 was collected then the solvent was removed under 
reduced pressure (279 mg, 0.6 mmol, 20% ). 
 
1H NMR (CDCl3, 400 MHz, δ ppm) 1.22-1.42 (m, 8H), 1.62-1.79 (m, 4H), 3.62 
(t, J= 6.5 Hz, 2H), 3.96 (t, J= 6.6 Hz, 2H), 5.23 (s, 2H), 6.96 (d, J=8.7 Hz, 2H), 
7.82 (d, J=8.8 Hz, 2H), 8.01-8.13 (m, 4H), 8.14-8.21 (m, 4H), 8.40 (d, J=9.2 Hz, 
1H), 9.88 (s, 1H). 
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13C NMR (CDCl3, 100 MHz, δ ppm) 25.8, 26.1, 29.0, 29.2, 29.8, 68.3, 70.4, 
71.5, 114.7, 123.6, 124.5, 125.0, 125.2, 125.9, 126.9, 127.3, 127.4, 127.6, 129.4, 
129.7, 130.8, 131.2, 131.3, 131.8, 132.0, 164.2, 190.8.  
HRMS-ESI: calculated for M+Na 487.2249, found 487.2217, ∆= 6.6 ppm  
 
2.2.2.3 Synthesis of 4-(prop-2-ynyloxy)benzaldehyde (5) 
 
Figure 25. Synthesis of compound 5 
 
4-hydroxybenzaldehyde (2.45 g, 20 mmol) and propargyl bromide (2.5 
g, 30 mmol) were dissolved in 100 ml acetonitrile. K2CO3 (5.5 g, mmol) and a 
few crystals of 18-crown-6 were added. The reaction was refluxed until all 4-
hydroxybenzaldehyde  consumed. The solvent was evaporated in vacuo, 
extracted with water and CHCl3. Organic layer was dried with Na2SO4 and 
evaporated  under reduced pressure. The product was purified by silica gel 
column chromatography using CHCl3/Hexane (50:50, v/v). Fraction containing 
compound 5 was collected then the solvent was removed under reduced pressure 
(2.85 g, 17.8 mmol, 89% ). 
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1H NMR (CDCl3, 400 MHz, δ ppm) 2.58 (t, J=2.5 Hz, 1H) 4.79 (dd, J=1.48, 0.9 
Hz), 7.11 (d, J=7.1 Hz, 2H), 7.87 (d, J=7.0 Hz, 2H), 9.92 (s, 1H). 
 
13C NMR (CDCl3, 100 MHz, δ ppm) 55.9, 76.4, 77.5, 115.2, 131.9, 162.4, 
190.8, 207.7.  
HRMS-ESI: calculated for M+Na 183.0422, found 183.0422, ∆= 0 ppm. 
 
2.2.2.4 Synthesis of 1,3,5,7-Tetramethyl-8-(4-Propargyloxiphenyl)-4,4-
difloroboradiaza-s-indacene (6) 
 
Figure 26. Synthesis of compound 6 
 
CH2Cl2 (300 ml) was purged with Ar for 30 min. 4-(prop-2-
ynyloxy)benzaldehyde 5 (1 g, 6.2 mmol) and 2,4-dimethyl pyrrole (1.2 g, 12.6 
mmol) were added. The color of the solution turned into red after the addition of 
3 drops of trifluoroacetic acid. The reaction mixture was stirred at room 
temperature for 12h. Then, tetrachloro-1,4-benzoquinone (1.52 g, 6.2 mmol) 
was added and the reaction mixture was stirred at room temperature for 45 min. 
Then triethyl amine (6 ml) and boron trifluoride diethyl etherate (6 ml) were 
added sequencially. After stirring at room temperature for 30 min, it was 
extracted with water. Organic layer was dried with Na2SO4 and evaporated  
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under reduced pressure. The product was purified by silica gel column 
chromatography using CHCl3 as mobile phase. Fraction containing compound 6 
was collected then the solvent was removed under reduced pressure (260 mg, 
0.68 mmol, 11% ). 
1H NMR (CDCl3, 400 MHz, δ ppm) 1.43 (s, 6H), 2.56-2.58 (m, 6H+1H), 4.77 
(d, J=2.4 Hz, 2H), 5.99 (s, 2H), 7.10 (d, J=8.7 Hz), 7.21 (d, J=8.7 Hz, 2H).  
13C NMR (CDCl3, 100 MHz, δ ppm) 14.5, 14.6, 56.0, 75.9, 78.0, 115.6, 121.2, 
128.0, 129.2, 131.8, 141.5, 143.1, 155.4, 158.1.  
HRMS-ESI: calculated for M+Na 401.1617, found 401.1644, ∆= 6.7 ppm.  
 
2.2.2.5 Synthesis of 2,6-Diiodo-1,3,5,7-tetramethyl-8-(4-Propargyloxiphenyl) 
-4,4-difloroboradiaza-s-indacene (7) 
 
Figure 27. Synthesis of compound 7 
1,3,5,7-Tetramethyl-8-(4-Propargyloxiphenyl)-4,4-difloroboradiaza-s-
indacene 6 (50 mg, 0.13 mmol) and I2 (83 mg, 0.33 mmol) were dissolved in 
ethanol (100 ml). Iodic acid, HIO3 (45.74 mg, 0.26 mmol) was dissolved in a 
few drops of water and added into previous solution. The reaction mixture was 
stirred at 60oC for a few hours untill all reeactant was consumed. Then, saturated 
sodium thiosulfate solution was added (50 ml)  and it was stirred at rrom 
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temparature for additional 30 min. Then, it was extracted with CHCl3 and water. 
Organic layer was dried with Na2SO4 and evaporated  under reduced pressure. 
The product was purified by silica gel column chromatography using 
CHCl3/Hexane (50/50, v/v). Fraction containing compound 7 was collected then 
the solvent was removed under reduced pressure (59 mg, 0.09 mmol, 72% ). 
 
1H NMR (CDCl3, 400 MHz, δ ppm) 1.36 (s, 6H), 2.49 (s, 1H), 2.56 (s, 6H), 4.70 
(s, 2H), 7.04 (d, J=8.8 Hz, 2H), 7.09 (d, J=8.8 Hz, 2H). 
13C NMR (CDCl3, 100 MHz, δ ppm) 16.0, 17.1, 56.1, 76.1, 85.8, 100.1, 116.0, 
127.8, 129.1, 131.6, 141.4, 146.0, 156.7, 158.6. 
HRMS-ESI: calculated for M+Na 652.9550, found 652.9515, ∆= 5.4 ppm. 
 
 2.2.2.6 Double Knoevenagel Condensation Reaction (8) 
 
2,6-Diiodo-1,3,5,7-tetramethyl-8-(4-Propargyloxiphenyl)-4,4-difloroboradiaza-
s-indacene 7 (38 mg, 0.06 mmol) and 1-(8-(4-formyl)-phenyloxiheksyloxi 
methyl)-pyrene 4 (70 mg, 0.15 mmol) dissolved in benzene (45 ml). Piperidine 
(0.2 ml) and glacial acetic acid (0.2 ml) were added. The solution was refluxed 
using Dean-Stark apparatus. When the solution was concentrated, reaction was 
followed by TLC until green-colored product became the major product. Then, 
benzene was evaporated in vacuo. It was extracted with CHCl3 and water. 
Organic layer was dried with Na2SO4 and evaporated  under reduced pressure. 
The product was purified by silica gel column chromatography using CHCl3 as 
mobile phase. Fraction containing compound 8 was collected then the solvent 
was removed under reduced pressure (40 mg, 0.026 mmol, 44% ). 
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Figure 28. Synthesis of compound 8 
 
1H NMR (CDCl3, 400 MHz, δ ppm) 1.15-1.78 (m, 30H), 2.61 (s, 1H), 3.61 (t, 
J= 6.6 Hz, 4H), 3.89 (t, J= 6.4 Hz, 4H), 4.81 (d, J=2.2 Hz, 2H), 5.21 (s, 4H), 
6.85 (d, J=8.7 Hz, 4H), 7.11 (d, J=8.8 Hz, 2H), 7.19 (d, J=8.8 Hz, 2H), 7.55-
7.64 (m, 4H+2H), 7.99-8.09 (m, 8H), 8.13-8.21 (m, 8H+2H), 8.39 (d, J=9.2 Hz, 
2H).  
13C NMR (CDCl3, 100 MHz, δ ppm) 15.1, 18.2, 22.3, 25.9, 26.1, 29.1, 29.2, 
29.3, 29.7, 29.8, 58.4, 68.0, 70.4, 71.5, 114.8, 123.6, 124.5, 125.1, 125.9, 126.9, 
127.3, 127.4, 127.6, 129.2, 129.4, 131.2, 131.3, 131.8, 132.0, 160.3.  
MALDI: calculated for 8, 1522.414, found 1522.319, ∆= 6.2 ppm. 
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2.2.2.7 Synthesis of Compound 1 (Click Reaction) 
 
Figure 29. Synthesis of compound 1. 
 
Click reaction was performed according to literature.152 Double 
Knoevenagel condension product, compound 8 (40 mg, 0.027 mmol) was 
dissolved in THF (2 ml). 2 molar equavalent CuI (10.3 mg, 0.054mmol), 50 
molar equavalent triethyl amine (135.6 mg, 1.34 mmol) and 2 molar equavalent 
1-azido polyethylene glycol (MW: 2000) (108 mg, 0.054 mmol) were added. 
The reaction mixture was stirred at room temperature for 12h, THF and triethyl 
amine were evaporated in vacuo. Organic layer was dried with Na2SO4 and 
evaporated  under reduced pressure. The product was purified by silica gel 
column chromatography using CHCl3/methanol (95/5, v/v). Fraction containing 
compound 1 was collected then the solvent was removed under reduced pressure 
(91 mg, 0.026 mmol, 95% ). 
 
1H NMR (CDCl3, 400 MHz, δ ppm) 1.19-1.42 (m, 16H), 1.47 (s, 6H), 1.60-1.71 
(m, 8H), 3.37 (s, 3H), 3.51-3.71 (m, “PEG” approximately 210H), 3.78-3.90 (m, 
8H), 5.17 (s, 4H), 5.25 (s, 2H), 6.84 (d, J=8.8 Hz, 4H), 7.11-7.17 (m, 4H), 7.53-
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7.62 (m, 4H+2H), 7.91 (s, 1H), 7.95-8.05 (m, 8H), 8.07-8.20 (m, 8H+2H), 8.45 
(d, J=9.2 Hz, 2H).  
13C NMR (CDCl3, 100 MHz, δ ppm) 17.6, 25.8, 26.0, 29.0, 29.2, 29.6, 29.7, 
46.9, 50.6, 59.0, 62.0, 68.0, 70.0, 70.6, 70.7, 71.9, 94.2, 106.0, 114.8, 123.5, 
124.4, 125.1, 126.9, 127.3, 127.4, 127.5, 129.2, 129.3, 130.8, 131.1, 131.8, 
139.1, 143.2, 150.4, 159.3, 160.3. 
MALDI: Distribution around 3298.384 with separation of 44.287 corresponding 
to etylene glycole unit.  
 
2.2.3 Non-covalent Functionalization of SWNT with Compound 1 
 
Compound 1 was adsorbed on to the SWNT by means of sonication and 
unadsorbed molecules were eliminated through filtration as described 
elsewhere.153 PBS buffer was prepared by dissolving 8 g NaCl, 0.2 g KCl, 1.44 
g Na2HPO4 and 0.24 g KH2PO4 in 1L water. 1 mM solution of photosensitizer 
was prepared by dissolving 70 mg compound 1 in 20 ml ethanol-PBS mixture 
(50/50, v/v).  3 mg SWNT  was put into a veil containing 5 ml 1:1 ethanol-PBS 
mixture and sonicated for 15 min. Then, 5 ml of previous solution was added 
into the viel.  The resultant mixture was sonicated for 1h while tempeature of the 
sonicator was maintained at around room temperature.  
The sample was centrifuged at 11000g for 2 hours to get rid of unsoluble 
SWNT via precipitation. Following this, the sample was centrifuged using 
Millipore 30kDa filter at 13000 g for 15 min to get rid of unadsorbed compound 
1. The filtrate was discarded and one more centrifugation was done. All green 
colored samples remained on the filter which was then collected into a tube by 
centrifugation of the filter upside down at 1000 g for 3 min.  
 Non-covalent attachment of compound 1 on SWNT was characterized 
through quenching of pyrene emission, AFM and TEM images. 
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2.2.4 Singlet Oxygen Generation Experiment 
 
Singlet oxygen generating capability of compound 1 and SWNT-
adsorbed compound 1 was done using singlet oxygen trap molecule 1,3-
diphenylisobenzofuran (DPBF). Singlet oxygen can be monitored using 
photobleaching and subsequent decrease in absorbance of DPBF as shown in 
Figure 21.  
 
Figure 30. Photobleaching of DPBF 
 
660 nm emitting 3000 mCd lead source was used as light source. A 
solution containing DPBF (50 µM) and SWNT-adsorbed compound 1 (62 nM ) 
was prepared in isopropanol. Concentration of the SWNT-adsorbed compound 1 
was determined by comparing its UV-absorbance to the absorbance of 
compound 1 solution with known concentration.  Another solution was prepared 
with same concentration of DPBF but with 62 nM compound 1 only. Both 
solutions were aerated for 5 minutes. Then, absorbance spectrum of  each 
solution was taken in 5 minutes intervals while the solutions were kept in dark. 
Then 660 nm light was exposed from 3-4 cm cell distance for 40 minutes and 
absorbance was taken in 5 minutes intervals for each solution. Same experiment 
was performed with a control solution of DPBF (50 µM) alone. 
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2.3 Experimental Part-II 
 
2.3.1 Design of the Light Harvesting Dendrimers 
 
Light harvesting dendrimer was designed in such a way that there is an 
efficient, unidirectional energy transfer from the terminal chromophore to the 
core of the dendrimer. This was achieved by convergent synthesis of dendrimer 
as seen in Figures 31-33. This design provides Förster type energy transfer 
(through space), thus, architectural structure of the dendrimer was determined 
taking spectral overlap of three different chromophores into account. Final 
acceptor chromophore was placed at the center of the dendrimer and other 
chromophores, mono styryl-BODIPY and BODIPY were placed accordingly.  
Chromophores were covalently attached to one another using facile click 
reactions. In order to compare energy transfer from BODIPY (orange) directly 
to monostyryl-BODIPY compound 21 was designed (Figure 31). To assess 
FRET from mono-styryl BODIPY (red) to di-styryl BODIPY (green), two 
different dendrimers were designed with a core di-styryl-BODIPY carying two 
or four mono-styryl-BODIPY, compounds 23 and 24 respectively (Figures 32-
33). Finally, cascade type light harvesting dendrimer composed of three 
different types of chromophores were designed as shown in Figure 33.  
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Figure 31. Structure of the light harvesting dendrimers (compound 21 and 23) 
 
(23) 
(21) 
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Figure 32. Structure of  light harvesting dendrimer (compound 24) 
 
(24) 
54 
 
 
 
Figure 33. Structure of light harvesting dendrimer (compound 25). 
 
(25) 
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2.3.2 Synthesis of Light Harvesting Dendrimers 
 
2.3.2.1 Synthesis of 4-(6-bromohexoxy)benzaldehyde (9) 
 
Figure 34. Synthesis of compound 9. 
 
1,4-hydroxybenzaldehyde (5 g, 41 mmol) and 1,8 dibromohexane (2 g, 
82 mmol) were dissolved in acetone (150 ml). K2CO3 (17.2 g, 123 mmol) and a 
few crystals of 18-crown-6 were added. The reaction mixture was refluxed for 
12h. Then, acetone was evaporated in vacuo and extracted with water and 
chloroform. Organic layer as dried with Na2SO4 and evaporated in vacuo. The 
product was purified by silica gel column chromatography using CHCl3/Hexane 
(75:25, v/v). Fraction containing compound  9 was collected then the solvent 
was removed under reduced pressure (6.7 mmol, 1.906 g, 16% ). 
  
1H NMR (CDCl3, 400 MHz, δ ppm) 1.35 (m, 4H), 1.65 (m, 4H), 3.4 (t, J= 6.68 
Hz, 2H),  3.88 (t, J= 6.4 Hz, 2H), 6. 82 (d, J= 8.76 Hz, 2H), 7.68 (d, J= 8.64 Hz, 
2H), 9.7 (s, 1H). 
13C NMR (CDCl3, 100 MHz, δ ppm) 25.24, 26.51, 28.83, 32.39, 44.91, 68.09, 
114.68, 129.73, 131.86, 164.08, 190.58. 
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2.3.2.2 Synthesis of 10-(4-(6-bromohexoxy)phenyl)-2,8-diethyl-5,5-difluoro-
1,3,7,9-tetramethyl-5H-dipyrrolo[1,2-c:1',2'-f][1,3,2]diazaborinin-4-ium-5-
uide (10) 
 
 
 
Figure 35. Synthesis of compound 10. 
 
CH2Cl2 (300 ml) was purged with Ar for 30 min. 4-(6-
bromohexoxy)benzaldehyde 9 (1.089 g, 3.82 mmol) and 2,4-dimethyl pyrrole 
(0.94 g, 7.7 mmol) were added. The color of the solution turned into red after 
the addition of 3 drops of trifluoroacetic acid. The reaction mixture was stirred 
at room temperature for 12h. Then, tetrachloro-1,4-benzoquinone (0.93 g, 3.82 
mmol) was added and the reaction mixture was stirred at room temperature for 
45 min. Then triethyl amine (8 ml) and boron trifluoride diethyl etherate (8 ml) 
were added sequencially. After stirring at room temperature for 30 min, it was 
extracted with water. Organic layer was dried with Na2SO4 and evaporated  
under reduced pressure. The product was purified by silica gel column 
chromatography using CHCl3 as mobile phase. Fraction containing compound 
10 was collected then the solvent was removed under reduced pressure (670 mg, 
1.2 mmol, 31% ). 
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1H NMR (CDCl3, 400 MHz, δ ppm) 1.0 (t, J= 7.52, 6H), 1.35 (s, 6H), 1.58 (m, 
4H), 1.85 (m, 4H), 2.3 (q, J= 7.56,  4H), 2.55 (s, 6H), 3.59 (t, J= 6.64 Hz, 2H),  
4.05 (t, J= 6.45 Hz, 2H), 7.0 (d, J= 8.56 Hz, 2H), 7.15 (d, J= 8.56 Hz, 2H). 
13C NMR (CDCl3, 100 MHz, δ ppm) 11.84, 12.46, 14.61, 17.06, 25.43, 26.67, 
29.11, 32.48, 44.96, 67.87, 114.95, 127.78, 129.44, 130.10, 132.60, 138.43, 
140.0, 153.46, 159.47.  
MALDI: calculated for M= 558.2229, found 558. 
 
2.3.2.3 Synthesis of 10-(4-(6-azidohexoxy)phenyl)-2,8-diethyl-5,5-difluoro-
1,3,7,9-tetramethyl-5H-dipyrrolo[1,2-c:1',2'-f][1,3,2]diazaborinin-4-ium-5-
uide (11) 
 
 
Figure 36. Synthesis of compound 11. 
 
10-(4-(6-bromohexoxy)phenyl)-2,8-diethyl-5,5-difluoro-1,3,7,9-tetra 
methyl-5H-dipyrrolo[1,2-c:1',2'-f][1,3,2]diazaborinin-4-ium-5-uide 10 (190 mg, 
0.34 mmol) was dissolved in 20 ml DMSO. Excess amount of sodium azide 
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(600 mg, 9.23 mmol) was added. The reaction mixture was stirred for 30 
minutes at 60oC. After 30 minutes, sample was extracted with water and CHCl3 
a few times to get rid of DMSO and excess NaN3. Organic layer containing 
compound 11 was dried with Na2SO4 and evaporated under reduced pressure No 
further purification was required. 
1H NMR (CDCl3, 400 MHz, δ ppm) 1.0 (t, J= 7.52 Hz, 6H), 1.35 (s, 6H), 1.54 
(m, 4H), 1.68 (m, 2H), 1.85 (m, 2H), 2.3 (q, J= 7.56 Hz,  4H), 2.55 (s, 6H), 3.32 
(t, J= 6.64 Hz, 2H),  4.05 (t, J= 6.45 Hz, 2H), 7.0 (d, J= 8.56 Hz, 2H), 7.15 (d, 
J= 8.56 Hz, 2H). 
13C NMR (CDCl3, 100 MHz, δ ppm) 11.84, 12.46, 14.62, 17.07, 25.71, 26.56, 
28.80, 29.13, 51.38, 67.86, 114.95, 127.77, 129.44, 131.19, 132.61, 138.43, 
140.33, 153.46, 159.46.  
HRMS-ESI: calculated for M+H 522.3216, found 522.3240, ∆= 0.8 ppm.  
 
2.3.2.4 Synthesis of (3,5-bis(prop-2-ynyloxy)phenyl)methanol (12) 
 
Figure 37. Synthesis of compound 12. 
 
5-(hydroxymethyl)benzene-1,3-diol (5 g, 35.7 mmol) was dissolved in 
200 ml acetone in round bottom flask. K2CO3 (5 g, 35.7 mmol) and a few 
crystals of 18-crown-6 were added. Propargyl bromide (10.5 g, 71.4 mmol) was 
added to the flask and the reaction mixture was refluxed for 24h. Then, acetone 
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was evaporated in vacuo and extracted with water and chloroform. Organic 
layer as dried with Na2SO4 and evaporated in vacuo. The product was purified 
by silica gel column chromatography using CHCl3/Methanol (97:3, v/v). 
Fraction containing compound  12 was collected then the solvent was removed 
under reduced pressure (30.5 mmol, 6.6 g, 86% ). 
 
1H NMR (CDCl3, 400 MHz, δ ppm) 2.45 (s, 2H), 4.60 (s, 6H), 6.49 (s, 1H), 6.51 
(s, 2H) as reported elsewhere.154 
 
2.3.2.5 Synthesis of 3,5-bis(prop-2-ynyloxy)benzaldehyde (13) 
 
Figure 38. Synthesis of compound 13. 
 
(3,5-bis(prop-2-ynyloxy)phenyl)methanol 12 (1 g, 4.625 mmol) was 
dissolved in 50 ml dichloromethane. Pyridinium chlorochromat (2 g, 9.25 
mmol) was added and the reaction mixture was stirred at room temperature. 
After 15 minutes all of the compound 12 was converted to compound 13 as 
followed by TLC. Dichloromethane was evaporated in vacuo  and the product 
was purified by silica gel column chromatography using CHCl3 as mobile phase. 
Fraction containing compound  13 was collected then the solvent was removed 
under reduced pressure. 
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1H NMR (CDCl3, 400 MHz, δ ppm) 2.58 (t, J=2.36 Hz, 2H), 4.73 (d, J=2.40 Hz, 
4H), 6.85 (t, J= 2.32 Hz, 1H), 7.1 (d, J=2.36 Hz, 2H), 9.9 (s, 1H).  
13C NMR (CDCl3, 100 MHz, δ ppm) 56.15, 76.27, 77.78, 108.8, 138.39, 159.09, 
191.42.   
 
2.3.2.6 Synthesis of 10-(3,5-bis(prop-2-ynyloxy)phenyl)-2,8-diethyl-5,5-
difluoro-1,3,7,9-tetramethyl-5H-dipyrrolo[1,2-c:1',2'-f][1,3,2]diazaborinin-
4-ium-5-uide (14) 
Figure 39. Synthesis of compound 14. 
 
CH2Cl2 (300 ml) was purged with Ar for 30 min. 3,5-bis(prop-2-
ynyloxy)benzaldehyde 13 (1.0 g, 4.6 mmol) and 2,4-dimethyl pyrrole (1.141 g, 
9.2 mmol) were added. The color of the solution turned into red after the 
addition of 3 drops of trifluoroacetic acid. The reaction mixture was stirred at 
room temperature for 12h. Then, tetrachloro-1,4-benzoquinone (1.12 g, 4.6 
mmol) was added and the reaction mixture was stirred at room temperature for 
45 min. Then triethyl amine (8 ml) and boron trifluoride diethyl etherate (8 ml) 
were added sequencially. After stirring at room temperature for 30 min, it was 
extracted with water. Organic layer was dried with Na2SO4 and evaporated  
under reduced pressure. The product was purified by silica gel column 
chromatography using CHCl3:Hexane (66:33, v/v) as mobile phase. Fraction 
61 
 
containing compound 14 was collected then the solvent was removed under 
reduced pressure (470 mg, 0.96 mmol, 21% ). 
1H NMR (CDCl3, 400 MHz, δ ppm) 1.0 (t, J= 7.48 Hz,  6H), 1.44 (s, 6H), 2.3 
(q, J=7.56 Hz, 4H), 2.5-2.55 (m, 6H+2H), 4.69 (d, J=2.08 Hz, 4H), 6.6 (d, 
J=2.28 Hz, 2H), 6.7 (t, J=2.28 Hz, 1H). 
13C NMR (CDCl3, 100 MHz, δ ppm) 11.54, 12.50, 14.63, 17.07, 56.04, 75.94, 
78.10, 103.50, 107.93, 130.39, 132.80, 137.56, 138.40, 139.18, 153.89, 159.35. 
HRMS-ESI: calculated for M+Na 489.2525, found 489.2509, ∆= -3.2 ppm.  
 
2.3.2.7 Synthesis of (E)-10-(3,5-bis(prop-2-ynyloxy)phenyl)-7-(4-(6-bromo 
hexyloxy)styryl)-2,8-diethyl-5,5-difluoro-1,3,9-trimethyl-5H-dipyrrolo[1,2-
c:1',2'-f][1,3,2]diazaborinin-4-ium-5-uide (15) 
 
Compound 9 (72 mg, 0.25 mmol) dissolved in benzene (45 ml). 
Piperidine (0.2 ml) and glacial acetic acid (0.2 ml) were added. The solution was 
refluxed using Dean-Stark apparatus. When the solution was concentrated, 
reaction was followed by TLC until purple-colored product became the major 
product. Then, benzene was evaporated in vacuo. It was extracted with CHCl3 
and water. Organic layer was dried with Na2SO4 and evaporated  under reduced 
pressure. The product was purified by silica gel column chromatography using  
Ethyl Acetate:Hexane (25:75, v/v) as mobile phase. Fraction containing 
compound 15 was collected then the solvent was removed under reduced 
pressure (78 mg, 0.1 mmol, 29% ). 
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Figure 40. Synthesis of compound 15. 
 
 
1H NMR (CDCl3, 400 MHz, δ ppm) 1.0 (t, J= 6.48 Hz,  3H), 1.18 (t, J= 7.56 
Hz), 1.45-1.55 (m, 3H + 3H + 4H), 1.82 (m, 4H), 2.33 (q, J=7.52 Hz, 2H), 2.5-
2.65 (m, 3H + 2H + 2H), 3.6 (t, J= 6.68 Hz, 2H), 4.05 (t, J= 6.44 Hz, 2H), 4.69 
(s, 4H), 6.6 (d, J=2.32 Hz, 2H), 6.7 (t, J=2.32 Hz, 1H), 6.9 (d, J= 8.6 Hz, 2H), 
7.19 (d, J= 16.69 Hz, 1H), 7.5 (d, J= 8.72 Hz, 2H), 7.62 (d, J= 16.72 Hz, 1H). 
13C NMR (CDCl3, 100 MHz, δ ppm) 11.27, 11,61, 12.75, 14.10, 14.56, 17.12, 
18.33, 25.41, 26.66, 29.08, 30.32, 32.52, 44.99, 56.07, 67.84, 75.91, 78.09, 
103.57, 108.14, 114.74, 117.89, 128.61, 130.19, 135.00, 137.73, 159.35, 159.58. 
HRMS-ESI: calculated for M+Na 755.2831, found 755.2811, ∆= 2.6 ppm.  
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2.3.2.8 Synthesis of 4-(6-azidohexoxy)benzaldehyde (16) 
 
 
Figure 41. Synthesis of compound 16. 
 
4-(6-bromohexoxy)benzaldehyde 9 (1.5 g, 5.3 mmol) was dissolved in 
25 ml DMSO. Sodium azide (1.37 g, 21.2 mmol) was added and the reaction 
mixture was stirred at 60oC for 2.5 hours. Then, it was extracted with water and 
CHCl3 a few times and organic layer was collected, dried with Na2SO4 and 
evaporated  under reduced pressure. No further purification was required.  
 
1H NMR (CDCl3, 400 MHz, δ ppm) 1.4-1.55 (m, 4H), 1.55-1.65 (m, 2H), 1.75-
1.85 (m, 2H), 3.28 (t, J=6.80 Hz, 2H), 4.05 (t, J=6.40 Hz, 2H), 7.00 (d, J=8.76 
Hz, 2H ), 7.82 (d, J= 7.86 Hz, 2H), 9.86 (s, 1H). 
13C NMR (CDCl3, 100 MHz, δ ppm) 25.57, 26.43, 28.74, 28.89, 51.31, 68.12, 
114.73, 129.80, 131.96, 164.14, 190.75.   
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2.3.2.9 Synthesis of 2,8-diethyl-5,5-difluoro-10-(4-methoxyphenyl)-1,3,7,9-
tetramethyl-5H-dipyrrolo[1,2-c:1',2'-f][1,3,2]diazaborinin-4-ium-5-uide (17) 
Figure 42. Synthesis of compound 17. 
 
CH2Cl2 (300 ml) was purged with Ar for 30 min. 4-methoxy 
benzaldehyde (394 mg, 2.89 mmol) and 2,4-dimethyl pyrrole (0.75 g, 5.78 
mmol) were added. The color of the solution turned into red after the addition of 
3 drops of trifluoroacetic acid. The reaction mixture was stirred at room 
temperature for 12h. Then, tetrachloro-1,4-benzoquinone (0.72 g, 2.89 mmol) 
was added and the reaction mixture was stirred at room temperature for 45 min. 
Then triethyl amine (6 ml) and boron trifluoride diethyl etherate (6 ml) were 
added sequencially. After stirring at room temperature for 30 min, it was 
extracted with water. Organic layer was dried with Na2SO4 and evaporated  
under reduced pressure. The product was purified by silica gel column 
chromatography using CHCl3 as mobile phase. Fraction containing compound 
17 was collected then the solvent was removed under reduced pressure (412 mg, 
1 mmol, 35% ). 
1H NMR (CDCl3, 400 MHz, δ ppm) 1.0 (t, J= 7.52 Hz,  6H), 1.35 (s, 6H), 2.3 
(q, J=7.56 Hz, 4H), 2.52 (s, 6H), 3.90 (s, 3H), 7.00 (d, J=8.76 Hz, 2H), 7.16 (d, 
J= 8.76 Hz, 2H), 
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13C NMR (CDCl3, 100 MHz, δ ppm) 11.81, 12.46, 14.61, 17.06, 55.30, 114.42, 
127.87, 129.46, 131.19, 132.62, 138.43, 140.27, 153.48, 159.99.  
HRMS-ESI: calculated for M+H 411.2419, found 411.2424, ∆= 0.2 ppm.  
 
2.3.2.10 Synthesis of 2,8-diethyl-5,5-difluoro-10-(4-methoxyphenyl)-1,9-
dimethyl-3,7-bis(4-(prop-2-ynyloxy)styryl)-5H-dipyrrolo[1,2-c:1',2'-f][1,3,2] 
diazaborinin-4-ium-5-uide (18) 
 
Figure 43. Synthesis of compound 18. 
 
Compound 17 (100  mg, 0.24 mmol) and 4-(prop-2-ynyloxy) 
benzaldehyde 5 (98 mg, 0.6 mmol) dissolved in benzene (45 ml). Piperidine (0.4 
ml) and glacial acetic acid (0.4 ml) were added. The solution was refluxed using 
Dean-Stark apparatus. When the solution was concentrated, reaction was 
followed by TLC until green-colored product became the major product. Then, 
benzene was evaporated in vacuo. It was extracted with CHCl3 and water. 
Organic layer was dried with Na2SO4 and evaporated  under reduced pressure. 
The product was purified by silica gel column chromatography using  Ethyl 
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Acetate:Hexane (25:75, v/v) as mobile phase. Fraction containing compound 18 
was collected then the solvent was removed under reduced pressure (150 mg, 
0.22 mmol, 90% ). 
 
1H NMR (CDCl3, 400 MHz, δ ppm) 1.15 (t, J= 7.48 Hz,  6H), 1.38 (s, 6H), 
2.55-2.65 (m, 4H+2H ), 3.90 (s, 3H), 4.75 (d, J=2.36 Hz, 4H), 7.00-7.06 (m, 4H 
+ 2H), 7.17-7.24 (m, 2H+2H), 7.06 (d, J=8.76 Hz, 4H), 7.70 (d, J=16.56 Hz, 
2H) 
13C NMR (CDCl3, 100 MHz, δ ppm) 11.67, 14.04, 18.00, 55.58, 56.04, 75.50, 
78.10, 115.20, 116.00, 118.50, 127.50, 128.69, 129.50, 130.00, 133.50, 158.00, 
159.50. 
HRMS-ESI: calculated for M+Na 717.3076, found 717.3060, ∆= -2.2 ppm.  
 
2.3.2.11 Synthesis of 10-(3,5-bis(prop-2-ynyloxy)phenyl)-2,8-diethyl-5,5-
difluoro-1,9-dimethyl-3,7-bis(4-(prop-2-ynyloxy)styryl)-5H-dipyrrolo[1,2-
c:1',2'-f][1,3,2]diazaborinin-4-ium-5-uide (19) 
 
Compound 14 (200  mg, 2.05 mmol) and 4-(prop-2-ynyloxy) 
benzaldehyde 5 (800.9 mg, 5 mmol) dissolved in benzene (45 ml). Piperidine 
(0.5 ml) and glacial acetic acid (0.5 ml) were added. The solution was refluxed 
using Dean-Stark apparatus. When the solution was concentrated, reaction was 
followed by TLC until green-colored product became the major product. Then, 
benzene was evaporated in vacuo. It was extracted with CHCl3 and water. 
Organic layer was dried with Na2SO4 and evaporated  under reduced pressure. 
The product was purified by silica gel column chromatography using  Ethyl 
Acetate:Hexane (20:80, v/v) as mobile phase. Fraction containing compound 19 
was collected then the solvent was removed under reduced pressure. 
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Figure 44. Synthesis of compound 19. 
 
1H NMR (CDCl3, 400 MHz, δ ppm) 1.15 (t, J= 7.44 Hz,  6H), 1.5 (s, 6H), 2.52 
(t, J=2.36 Hz, 2H), 2.55 (t, J=2.36 Hz, 2H), 2.63 (q, J=7.56 Hz, 4H), 4.70 (d, 
J=2.4 Hz, 4H), 4.75 (d, J= 2.36 Hz, 4H), 6.63 (d, J=2.32 Hz, 2H), 6.72 (t, J=2.28 
Hz, 1H), 7.05 (d, J=8.80 Hz, 4H), 7.21 (d, J=16.77 Hz, 2H), 7.60 (d, J=8.80 Hz, 
4H), 7.68 (d, J= 16.73 Hz, 2H).  
13C NMR (CDCl3, 100 MHz, δ ppm) 11.37, 14.04, 18.39, 55.89, 56.08, 75.73, 
75.94, 78.10, 103.61, 108.32, 115.22, 118.58, 128.73, 130.00, 131.17, 135.26, 
137.86, 158.04, 159.37. 
HRMS-ESI: calculated for M+Na 795.3182, found 795.3199, ∆= 2.2 ppm.  
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2.3.2.12 Synthesis of (E)-7-(4-(6-azidohexyloxy)styryl)-2,8-diethyl-5,5-
difluoro-10-(4-methoxyphenyl)-1,3,9-trimethyl-5H-dipyrrolo[1,2-c:1',2'-
f][1,3,2]diazaborinin-4-ium-5-uide (20) 
Figure 45. Synthesis of compound 20. 
 
Compound 17 (410 mg, 1 mmol) and 4-(6-azidohexoxy) benzaldehyde 
16 (120 mg, 0.49 mmol) dissolved in benzene (45 ml). Piperidine (0.5 ml) and 
glacial acetic acid (0.5 ml) were added. The solution was refluxed using Dean-
Stark apparatus. When the solution was concentrated, reaction was followed by 
TLC until purple-colored product became the major product. Then, benzene was 
evaporated in vacuo. It was extracted with CHCl3 and water. Organic layer was 
taken, dried with Na2SO4 and evaporated  under reduced pressure. The product 
was purified by silica gel column chromatography using  Ethyl Acetate:Hexane 
(20:80, v/v) as mobile phase. Fraction containing 20 was collected then the 
solvent was removed under reduced pressure (100 mg, 0.16 mmol, 16 %) 
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1H NMR (CDCl3, 400 MHz, δ ppm) 1.0 (t, J= 7.48 Hz,  3H), 1.15 (t, J= 7.56 Hz, 
3H), 1.36 (s, 3H), 1.38 (s, 3H), 1.50 (m, 4H), 1.68 (m, 2H), 1.84 (m, 2H), 2.34 
(q, J= 7.48 Hz, 2H), 2.58 (m, 2H+3H), 3.32 (t, J= 6.84 Hz, 2H), 3.90 (s, 3H), 
4.02 (t, J=6.32 Hz, 2H), 6.91 (d, J=8.72 Hz, 2H), 7.03 (d, J=8.68 Hz, 2H), 7.15-
7.22 (m, 2H+1H), 7.54 (d, J=8.76 Hz, 2H), 7.62 (d, J=16.69 Hz, 1H) 
13C NMR (CDCl3, 100 MHz, δ ppm) 11.58, 11.91, 12.71, 14.11, 14.56, 17.11, 
18.32, 25.68, 26.52, 28.81, 29.11, 51.40, 55.33, 67.81, 114.44, 114.72, 118.00, 
128.03, 128.57, 129.65, 130.27, 134.73, 138.63, 149.90, 155.00, 159.49, 160.02. 
HRMS-ESI: calculated for M+Na 640.3634, found 640.3604, ∆= -4.8 ppm.  
 
2.3.2.13 Synthesis of Compound 21 (Click Reaction) 
 
Synthesis was done according to literature.155 Compound 11 (107 mg, 
0.21 mmol) and compound 15 (78 mg, 0.1 mmol) were dissolved in 8 ml THF. 
A few drops of Et3N was added and the reaction mixture was stirred for 5 
minutes at room temperature. In a viel, CuSO4.5H2O (30% mole equavalent of 
compound 15, 7.5 mg, 0.03 mmol) was dissolved in 4 ml water separately. 
Sodium ascorbate (60% mole equavalent of compound 15, 11.88 mg, 0.06 
mmol) was dissolved in 4 ml water in another viel. Solutions of sodium 
ascorbate and CuSO4 were added to the first reaction mixture sequantially and 
the resultant mixture was stirred at room temperature untill all compound 15 
was consumed, as followed by TLC. Then, it was extracted with CHCl3 and 
water. Organic layer was dried with Na2SO4 and evaporated  under reduced 
pressure. The product was purified by silica gel column chromatography using  
CHCl3 as mobile phase. Fraction containing compound 21 was collected then 
the solvent was removed under reduced pressure (65 mg, 0.035mmol, 35 % ). 
1H NMR (CDCl3, 400 MHz, δ ppm) 1.0 (m, 15H), 1.16 (t, J= 7.40 Hz, 3H), 1.34 
(s, 12H), 1.42-1.62 (m, 3H + 3H + 12H), 1.84 (m, 8H), 2.00 (m, J= 8H), 2.3 (m, 
8H + 2H), 2.54 (s, 12H), 2.58-2.64 (m, 2H+3H), 3.58 (t, J=6.68 Hz, 2H), 4.01 
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(m, 6H), 4.42 (t, J=7.12 Hz, 4H), 5.20 (s, 4H), 6.61 (d, J=2.20, 2H), 6.78 (t, 
J=2.20 Hz, 1H), 6.90 (d, J= 8.76 Hz, 2H), 6.98 (d, J=8.60 Hz, 4H), 7.15 (d, 
J=8.52, 4H), 7.19 (d, J=16.286 Hz, 1H), 7.54 (d, J=8.72 Hz, 2H), 7.61 (d, 
J=16.85 Hz, 1H), 7.66 (s, 2H). 
 
Figure 46. Synthesis of compound 21 
 
13C NMR (CDCl3, 100 MHz, δ ppm) 11.32, 11.66, 11.85, 12.46, 14.10, 14.57, 
14.62, 17.06, 25.40, 25.61, 26.37, 26.66, 29.08, 30.25, 32.51, 44.99, 50.36, 
62.27, 67.75, 67.84, 100.00, 102.00, 108.00, 114.75, 114.91, 122.64, 127.83, 
128.61, 129.46, 130.13, 132.62, 135.05, 137.86, 138.40, 140.27, 143.44, 153.49, 
159.41, 160.22.  
71 
 
MALDI: calculated for compound 21 1782.8871, found 1755. 
 
2.3.2.14 Synthesis of Compound 22 
Figure 47. Synthesis of compound 22. 
 
Compound 21 (40 mg, 0.022 mmol) and sodium azide (7.23 mg, 0.11 
mmol) was dissolved in 15 ml acetonitrile. A few crystals of 18-crown-6 was 
added and the reaction mixture was stirred 2 days at 60oC. Then, it was 
extracted with ethyl acetate and water. Organic layer was collected, dried with 
Na2SO4 and evaporated  under reduced pressure. No further purification was 
required.  
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1H NMR (CDCl3, 400 MHz, δ ppm) 1.0 (m, 15H), 1.16 (t, J= 7.16 Hz, 3H), 1.34 
(s, 12H), 1.42-1.62 (m, 3H + 3H + 12H), 1.84 (m, 8H), 2.00 (m, 8H), 2.3 (m, 8H 
+ 2H), 2.50-2.65 (m, 12H+2H+3H), 3.30 (t, J=6.84 Hz, 2H), 4.05 (m, 6H), 4.42 
(t, J=7.12 Hz, 4H), 5.20 (s, 4H), 6.61 (d, J=1.68, 2H), 6.78 (t, J=2.20 Hz, 1H), 
6.90 (d, J= 8.56 Hz, 2H), 6.98 (d, J=8.28 Hz, 4H), 7.15-7.20 (m,4H+1H), 7.54 
(d, J=8.60 Hz, 2H), 7.61 (d, J=16.53 Hz, 1H), 7.66 (s, 2H). 
  
2.3.2.15 Synthesis of Compound 23 (Click Reaction) 
 
Synthesis was done according to literature.155 Compound 18 (22 mg, 
0.03 mmol) and compound 20 (60 mg, 0.094 mmol) were dissolved in 3 ml 
THF. A few drops of Et3N was added and the reaction mixture was stirred for 5 
minutes at room temperature. In a viel, CuSO4.5H2O  (30% mole equavalent of 
compound 18, 2.3 mg, 0.009 mmol) was dissolved in 1.5 ml water separately. 
Sodium ascorbate (60% mole equavalent of compound 18, 3.6 mg, 0.018 mmol) 
was dissolved in 1.5 ml water in another viel. Solutions of sodium ascorbate and 
CuSO4 were added to the first reaction mixture sequantially and the resultant 
mixture was stirred at room temperature untill all compound 18 was consumed, 
as followed by TLC. Then, it was extracted with CHCl3 and water. Organic 
layer was dried with Na2SO4 and evaporated  under reduced pressure. The 
product was purified by silica gel column chromatography using  
CHCl3:Methanol (95:5, v/v)  as mobile phase. Fraction containing compound 23 
was collected then the solvent was removed under reduced pressure. 
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Figure 48. Synthesis of compound 23. 
 
1H NMR (CDCl3, 400 MHz, δ ppm) 1.0 (t, J= 7.52 Hz,  6H), 1.15 (M, 12H), 
1.35 (m, 12H+6H+2H), 1.54 (m, 4H), 1.78 (m, 4H), 1.98 (m, 4H), 2.32 (m, 4H), 
2.55-2.65 (m, 6H+8H), 3.9 (s, 9H), 3.98 (t, J= 6.20 Hz, 4H), 4.4 (m, 4H), 5.3 (s, 
4H), 6.88 (d, J= 8.80 Hz, 4H), 7.03 (m, 4H+2H+4H), 7.12-7.24 (m, 
4H+2H+4H), 7.52 (d, J= 8.72 Hz, 4H), 7.55-7.65 (m, 2H+4H+2H), 7.68 (d, J= 
16.61 Hz, 2H) 
13C NMR (CDCl3, 100 MHz, δ ppm) 11.91, 12.72, 14.06, 14.11, 14.57, 17.11, 
18.32, 18.38, 25.50, 26.23, 28.97, 30.19, 50.33, 55.33, 62.19, 67.68, 114.44, 
114.47, 114.72, 115.15, 122.58, 128.02, 128.55, 128.77, 129.65, 129.85, 130.24, 
130.86, 134.73, 158.72, 159.47, 160.02, 160.06. 
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MALDI: calculated for compound 23 1973.0291, found 1973. 
 
2.3.2.16 Synthesis of Compound 24 (Click Reaction) 
 
Synthesis was done according to literature.155 Compound 19 (13.3 mg, 
0.017 mmol) and compound 20 (55 mg, 0.086 mmol) were dissolved in 3 ml 
THF. A few drops of Et3N was added and the reaction mixture was stirred for 5 
minutes at room temperature. In a viel, CuSO4.5H2O  (21.5 mg, 0.086 mmol) 
was dissolved in 1.5 ml water separately. Sodium ascorbate (25.6 mg, 0.129 
mmol) was dissolved in 1.5 ml water in another viel. Solutions of sodium 
ascorbate and CuSO4 were added to the first reaction mixture sequantially and 
the resultant mixture was stirred at room temperature untill all compound 19 
was consumed, as followed by TLC. Then, it was extracted with CHCl3 and 
water. Organic layer was dried with Na2SO4 and evaporated  under reduced 
pressure. The product was purified by silica gel column chromatography using 
CHCl3 as mobile phase and then CHCl3:Methanol (98:2, v/v) as mobile phase. 
Fraction containing compound 24 was collected then the solvent was removed 
under reduced pressure.   
1H NMR (CDCl3, 400 MHz, δ ppm) 0.8-1.65 (m, 24H+24H+8+8+8+6+6), 1.75 
(m, 8H), 1.95 (m, 8H), 2.32 (m, 8H), 2.6 (m, 20H+4H), 3.9 (s, 12H), 4.00 (m, 
8H), 4.40 (m, 8H), 5.2 (m, 8H), 6.6 (d, J= 3.84 Hz, 2H), 6.9 (m, 8H+4H+1H), 
7.00 (m, 8H+4H), 7.1-7.25 (m, 8H+ 4H + 2H), 7.45-7.70 (m, 
4H+8H+2H+4H+4H).  
MALDI: calculated for compound 24, 3329.7508, found 3329. 
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Figure 49. Synthesis of compound 24 
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2.3.2.17 Synthesis of Compound 25 (Click Reaction) 
 
Synthesis was done according to literature.155 Compound 19 (4.39 mg, 
0.0057 mmol) and compound 43 (50 mg, 0.028 mmol) were dissolved in 3 ml 
THF. A few drops of Et3N was added and the reaction mixture was stirred for 5 
minutes at room temperature. In a viel, CuSO4.5H2O  (19 mg, 0.076 mmol) was 
dissolved in 0.75 ml water separately. Sodium ascorbate (35.1 mg, 0.177 mmol) 
was dissolved in 0.75 ml water in another viel. Solutions of sodium ascorbate 
and CuSO4 were added to the first reaction mixture sequantially and the 
resultant mixture was stirred at room temperature untill all compound 19 was 
consumed, as followed by TLC. Then, it was extracted with CHCl3 and water. 
Organic layer was dried with Na2SO4 and evaporated  under reduced pressure. 
The product was purified by silica gel column chromatography using 
CHCl3:Methanol (95:5, v/v) as mobile phase. Fraction containing compound 25 
was collected then the solvent was removed under reduced pressure.   
1H NMR (CDCl3, 400 MHz, δ ppm) 1.0 (m, 60H), 1.18 (m, 12H+6H), 1.22-1.70 
(m, 120H + 6H + 8H), 1.82 (m, 32H), 2.00 (m, 24H), 2.34 (m, 40H), 2.5-2.64 
(m, 12H+8H+48H+4H), 4.00 (m, 16H+8H), 4.40 (m, 16H+8H), 5.2 (m, 
16H+8H), 6.6 (8H+2H), 6.79 (4H+1H), 6.86 (8H), 7.00(16H+4H), 7.18 
(16H+4H+2H), 7.48-7.62 (8H+4H+4H+2H), 7.65 (8H+4H). 
MALDI: calculated for compound 25, 7812.3031, found 7794.  
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Figure 50. Synthesis of compound 25. 
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CHAPTER 3 
 
RESULTS AND DISCUSSIONS 
 
3.1 SWNT as a Delivery System for Photosensitizer 
 
Carbon nanotubes are suitable delivery system for drugs and related 
agents when their biocompatibility and easy non-covalent modifications are 
considered. In this research, SWNT is used for delivery agent for photodynamic 
therapy reagent. Photodynamic therapy is a growing field of research due to 
promising results obtained in clinical applications. This approach allows local 
treatment of tumors and gives minimum damage to surrounding normal tissue 
compared to other conventional therapies such as radio or chemotherapies. Even 
in the absence of specific targeting group, photosensitizers tend to localize in 
tumor tissue due to enhanced permeation and retention in this region, in addition 
light is exposed to only region of interest maintaining further selectivity.  
Here, we present a novel photodynamic therapy reagent based on 
BODIPY where SWNT is used as delivery system. BODIPY core was 
synthesized through standard BODIPY reactions. BODIPY is preferred due to 
its photostability and high extinction coefficient.45 Besides, core BODIPY can 
be modified in a number of regions easily.45 In this research for instance, 2, 6 
positions were decorated with iodines. Spin forbidden transition from singlet 
excited state of photosensitizer to triplet state is enhanced in the presence of 
heavy atom as a result of increased spin-orbit coupling.32 Thus, iodination 
maintains this in our design.  
Methyl groups in 3, 5 positions are acidic to participate in Knoevenagel 
condensation reactions. Hence, we obtained distyryl-BODIPY with pyrene 
containing moiety for the attachment on SWNT. Previously, SWNT-pyrene pi-pi 
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interaction was well studied and high stability against desorption was 
reported.90-91 Recently, Akkaya et al. discovered that modification in 1, 7 
positions of BODIPY is also possible through same kind of reaction 
(unpublished data). 
Via facile click reaction polyetylene glycol moiety was attached to the 
photensitizer to maintain water solubility and nonspecific binding of proteins on 
the walls of SWNT.156 PEG also increases blood circulation time of 
photosensitizer as reported by Liu and Dai et al.157 All the compounds obtained 
after each reaction were characterized using 1H, 13C NMR spectra and Mass 
spectrometry analysis. NMR spectra were measured using CDCl3 as solvent. All 
these data are given in appendices A and B.  
Maximum absorbance wavelength of photosensitizer is determined to be 725 
nm in aqueous solution (Figure 51) which is very suitable for PDT applications 
since penetration depth of light of this wavelength, namely, light in near IR 
region, is considerably high. 
Figure 51. Absorbance of compound 1 in ethanol-PBS mixture (50/50, v/v). Black line: 
compound 1 before adsorption on to SWNT; red line: compound 1 after adsorption on to SWNT. 
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Non-covalent attachment of pyrene containing photosensitizer on SWNT 
was performed through sonication method as reported elsewhere.153 Through 
sonication, nanotube bundles are expected to be disrupted and dispersed. 
Attachment of PEG containing PS solubilizes nanotubes afterwards. Through 
filtration method, unattached, free compound 1 was eliminated. Millipore filter 
used for this purpose allows the passage of small molecules, molecules with 
molecular mass lower than 30kDa, thus only free compound 1 can pass through 
pores of filter. Strikingly, the filtrate was transparent indicating, owing to strong 
pyrene-SWNT interaction, only spectroscopically insignificant, minute amount 
of compound 1 remains unattached.  
 
Figure 52. Fluorescence spectrum of compound 1 in ethanol-PBS mixture (50/50, v/v) excited 
at 343 nm. Red line: compound 1 before adsorption on SWNT; blue line: compound 1 after 
adsorption on SWNT.  
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Pyrene emission was reported to be quenched after such attachment due to 
electron transfer from pyrene to SWNT.158-159 In this research, this phenomenon 
is confirmed, thus pyrene-SWNT attachment was demonstrated. Upon excitation 
at 343 nm, almost three folds quenching of pyrene emission due to stacking of 
compound 1 on to the SWNT was observed (Figure 52) compared with the non-
stacked compound 1 with equal absorbance (Figure 51).  
Apart from quenching in pyrene emission, pyrene-SWNT non-covalent 
functionalization was characterized using atomic force microscopy (AFM) and 
high resolution transmission electron microscopy (TEM) measurements (Figure 
53).  Nanotubes are seen as separate entities rather than bundles in TEM image 
indicating that solubilization process was successful.153 Besides, using non-
contact mode, roughness of a few nanometer heights on SWNT was measured 
which clearly points out the presence of bulky molecule on otherwise smooth 
SWNT (Figure 54).160-161  
  
 
 
 
 
 
 
 
 
Figure 53. TEM image of SWNT functionalized with compound 1. 
 
20 
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Figure 54. (a) AFM image of compound 1-SWNT. (b) AFM 3D topographic view. PSIA 
XE-100E AFM and Multi75AI tip was used in noncontact mode with resonance frequency 
75 KHz and force constant 3.0 N/m. 
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Singlet oxygen generation capability of compound 1 with and without 
SWNT was measured using photobleaching of singlet oxygen trap molecule 1,3-
diphenylisobenzofuran (DPBF). As shown in Figure 21, DPBF reacts with 1O2 
and absorbance at 411 nm decreases consequently. 1O2 is generated by excited 
photosensitizer. Since DPBF is soluble in isopropanol, experiment was 
performed in this solution. Maximum absorbance wavelength of compound 1 
with SWNT in isopropanol is at about 666 nm, thus array of LEDs emitting 660 
nm light is appropriate for excitation of PS (Figure 55).  
 
 
Figure 55. Absorbance spectrum of SWNT-adsorbed compound 1 in isopropanol.  
 
 
We performed same experiment with three different samples. In control 
experiment, only 50 µM DPBF containing solution was monitored for 5 minutes 
intervals for 15 min in dark and 40 min under 660 nm light illumination. No 
significant decrease in absorbance was detected even under irradiation as shown 
in Figure 56 and Figure 57 as expected. Same experiment was performed with 
same concentration of DPBF together with 62 nM compound 1 only and 
compound 1 stacked on SWNT. Results indicate that photobleaching rate is 
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slightly higher in sample containing free compound 1. However, this difference 
in rate of photobleaching is not too important to obstruct phodynamic action of 
photosensitizer, namely singlet oxygen generation capability. SWNTs are 
known to react with 1O2 and act as scavenger 1O2 to some extent.162-163 This 
would be the reason of minor decrease in photobleaching rate. However, the 
alkyl-spacer between SWNT binding moiety and BODIPY core seems to be 
effective in preserving PDT ability of PS by separating donor-acceptor moieties 
hence reduces quenching.  
 
Figure 56. Bleaching of 50 µM DPBF in isopropanol in the presence of 62  nM SWNT-
adsorbed compound 1. For the first 15 minutes sample was kept at dark, then irradiated with 660 
nm light for 40 minutes. Absorbance was measured in 5 minutes intervals. 
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Figure 57. Absorbance of DPBF in isopropanol at 411 nm without compound 1 (square), in the 
presence of compound 1 only (triangle) and in the presence of compound 1 non-covalently 
attached to SWNT (circle).  
 
 
3.2 Light Harvesting Dendrimer 
 
In the knowledge of science, understanding the working principles of 
biological systems provides direct use of experience of millions of years of 
evolutionary processes. Living organisms naturally select certain traits that are 
tuned to work efficiently under earths’ conditions. One such marvelous trait is 
their ability to use sun energy. Living in a world where energy demand is 
severely increasing, understanding and mimicking such traits are becoming 
meaningful. Thus, array of chromophores that harvest light efficiently is a 
primitive but promising approach.  
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In this research, four different light harvesting dendrimers were designed 
and synthesized. Efficient and unidirectional energy transfer from the terminal 
units to the interior of the dendrimer was achieved by convergent synthesis. The 
light harvesting system was designed to allow Förster type resonance energy 
transfer in a cascade from the surface of the dendrimer to the core. Placement of 
each chromophore on the structure of the dendrimer was determined taking 
spectral overlap between adjacent chromophores into account.  Final acceptor 
unit, distyryl BODIPY was placed at the center of the dendrimer and other 
chromophores, mono styryl-BODIPY and BODIPY were located in the outer 
shell of the dendrimer in succession. Through out this chapter, BODIPY, 
monostyryl-BODIPY and distyryl-BODIPY were shown in orange, red and 
green respectively. To assess energy transfer from mono-styryl BODIPY to di-
styryl BODIPY, two dendrimers were synthesized with a core di-styryl-
BODIPY carying two or four mono-styryl-BODIPYs (23 and 24 in that order). 
Direct energy transfer from BODIPY to monostyryl-BODIPY was examined 
using 21 that carries two BODIPY attached to one monostyryl-BODIPY.  
  BODIPYs were synthesized using standard BODIPY reactions and in 
order to construct spectrally appropriate chromophores, conjugation was 
extended through Knoevenagel condensation reactions. Chromophores were 
covalently attached to one another using facile copper (I) catalyzed click 
reactions between azido and ethynyl groups of compounds. Azido compounds 
were characterized monitoring 1H NMR shift from δ3.5 to δ3.3 as the bromo 
reagent is consumed to generate azido product. Click reaction products have 
distinct singlet peak at around δ7.6 in 1H NMR corresponding to triazole 
hydrogen.  
 Photophysical characterization shown in Table 2 confirms that as the 
number of specific BODIPY units increases, extinction coefficient at that 
BODIPY’s maximum absorbance wavelength increases in accordance. 
Extinction coefficient of BODIPY (11) was determined to be 76154 at 526 nm. 
This number increases to 539807 in compound 25 which carries 8 BODIPY 
units. This increase is more than 7-folds which is consistent with the number of 
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BODIPYs on the structure. In compounds 23 and 24, increase in monostyryl-
BODIPY extinction coefficient is 2.2 and 4.5 folds respectively, consistent with 
number of this units, 2 and 4 in each compound in that order.  
 
Table 2. Photophysical properties of  dendrimers and dendrimer elements. 
Compound 
 
ε (λmax) 
 (M-1cm-1)(nm) 
λem 
(nm) 
ΦF 
λexc(488nm) 
ΦF 
λexc(550nm) 
ΦF 
λexc(610nm) 
11 76154 (526) 539 0.80 - - 
15 59434 (590) 605 - 0.85 - 
18 71214 (651) 670 - - 0.67 
19 71587 (653) 672 - - 0.68 
20 - 624 - 0.89 - 
21 - 605 0.14  - 
23 63850 (654) 
131539 (590) 
605 
672 
- 0.08 (605) 
0.42 (672) 
- 
24 88084 (656) 
269745 (590) 
605 
672 
- 0.06 (605) - 
25 81875 (655) 
298750 (590) 
539807(527) 
539 
605 
672 
- 
- 
0.02 
- 
0.09 
- 
- 
- 
- 
 
 Quantum yields were calculated using three different standard 
chromophores, Rhodamine 6G (488 nm, water), Sulforhodamine 101 (550 nm, 
ethanol) and Cresyl Violet (610 nm, methanol) and given in table 2. Formula 6 
given at page 37 was used for calculations. Since for accuracy, absorbance and 
emission spectra of standard and sample should be overlapping, no ideal 
standard exists to calculate the quantum yields of dendrimers, absorbing at 520 
nm, emitting at 672 nm. Thus, calculations were done for those having 
satisfactory overlap in each spectrum. Otherwise, lack of overlap would lead to 
underestimation of quantum yields, hence misleading.  
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Figure 58. Excitation spectra of compounds 21, 23, 24 and 25. 
 
 Excitation spectra are given in Figure 58. As it can be seen in Figures 59, 
62, 65, 68, absorbance spectra of compounds 21, 23, 24 and 25 show distinct 
peaks (526 nm, 590 nm, 653nm) corresponding to individual chromophores in 
the structure of the dendrimer, which indicates absence of ground state 
interactions between different units of dendrimer. 
 In order to understand energy transfer between BODIPYand mono-styryl 
BODIPY in the absence of di-styryl BODIPY, FRET efficiency in compound 21 
was analyzed. Even though, 11 and 21 absorb equally at 526 nm, corresponding 
emission at 539 nm was quenched significantly in 21 due to FRET (Figure 59, 
60). In addition, highly enhanced emission at 605 nm (more than 8-fold 
increase) compared to 15, was observed even when the compound 21 was 
excited from BODIPY. Energy trsnsfer from outer BODIPY is also obvious 
considering the decrease in quantum yield from 0.80 to 0.14 upon excitation at 
BODIPY’s absorbance wavelength for compound 21 (Table 2).  Consistently, 
lifetime of BODIPY decreased from 4.3 ns to 0.14 ns (Table 3).  
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Figure 59. Absorbance spectra of compoıunds 11, 15 and 21. 
 
 
Figure 60. Emission spectra of compounds 11, 15 and 21 with equal absorbance. 
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Figure 61. Comparison of emissions of compound 21 excited at 525(solid line) and 585 nm 
(dashed line). 
 
 For compound 21, excitation at 525 nm results in enhancement in 
emission of acceptor monostyryl BODIPY. Much more interestingly, emission 
upon excitation at 525 nm is more than emission upon excitation at core’s own 
absorption maxima, namely at 585 nm (Figure 61). This indicates nothing but 
efficient channeling of energy to the core from the surrounding BODIPY 
moieties.   
 FRET efficiencies can be calculated either using steady state or time-
resolved method. The latter is accepted to be more accurate since it lacks 
problems associated with inner filter effect and integration errors. Comparing 
the results obtained using quantum yields (steady state approach) or excited state 
lifetimes of donor alone and donor in the presence of acceptor (time-resolved 
approach), shows that in steady for compound 21, first method slightly 
underestimate the energy transfer efficiency. 83% and 97% efficiency were 
found using each method respectively. Being more accurate, FRET efficiency 
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calculations were done using time-resolved method (Formula 7 and 8) at page 
29, which estimates 97% efficiency of FRET from outer BODIPY units to 
distyryl BODIPYs. For some other compounds however, quantum yields were 
used since lifetime data is not available yet. For all calculations, lifetime of 
BODIPY was taken to be 4.3 ns as tabulated elsewhere.164 For compound 21, 
rate of energy transfer was determined to be 6.91*109 s-1. Lifetime of donor 
BODIPY, (compound 11) decreases significantly from 4.3 ns to 0.14 ns, which 
can be attributed to energy transfer. All available lifetimes, FRET rate constants 
and calculated FRET efficiencies were given in Table 3. Rate constants were 
calculated using Equation 7 on page 29 or for those of compounds lacking τDA, 
following formula was used.126 
   kFRET = 1/τD [(1/εFRET)-1]-1               (10) 
 
 
Table 3. Lifetimes, FRET rate constants and efficiencies of compounds. 
Compound τ (ns) kFRET(s-1) εFRET 
λem(529) λem(605) λem(675) 
15 - 5.57 - - - 
19 - - 4.97 - - 
20 - 4.57 - - - 
21 0.14 5.03 - 6.91*109 97% 
23 - - 4.80 2.21 *109 91% 
24 - - 4.44 2.9 *109 93% 
25; exc 526 nm 0.31 - 4.6 3.09*109 93% 
25; exc 585 nm - - - 1.97 *109 90% 
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Figure 62. Absorbance spectra of compounds 18, 20, 23. 
 
 
Figure 63. Emission spectra of compounds 18, 20 and 23 with equal absorbance excited at 585 
nm  
93 
 
 
Figure 64. Comparison of emission of 23 excited at 585 nm (solid line) and 645 nm (dashed 
line) 
 
 To determine FRET efficiency from monostyryl-BODIPY to core 
distyryl-BODIPY two different dendrimers; compounds 23 and 24 were 
synthesized. With equal absorbance (Figure 62 and 65) emission spectra of these 
compounds were analyzed (Figure 63 and 66). Emission of distyryl BODIPY at 
624 nm decreased more than 5-folds in each compound. Energy transfer 
efficiencies from monostyryl to distyryl BODIPYs were determined to be 91% 
and 93% for 23 and 24 respectively. Quantum yield calculations indicate a 
decrease from 0.89 (compound 20) to 0.08 (compound 23) and 0.06 (compound 
24) for emission at 624 nm corresponding to distryl-BODIPY emission which is 
expected.Furthermore, as it can be seen in Figure 64 and 67, both compounds 23 
and 24 display higher emission intensity upon excitation at donor’s absorption 
wavelength compared to excitation at acceptor’s own absorption wavelength.  
All these data undoubtly confirms efficient FRET from monostyryl to distyryl-
BODIPY in each dendrimer. 
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Figure 65. Absorbance spectra of compounds 19, 20 and 24. 
 
 
Figure 66. Emission spectra of compounds 19, 20 and 24 with equal absorbance excited at 585 
nm. 
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Figure 67. Comparison of emission of 24 excited at 585 nm (solid line), 645 nm (dashed line). 
 
 
Figure 68. Absorbance spectra of compounds 11, 15, 19, 25. 
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Figure 69. Emission spectra of compounds 11, 19 and 25 with equal absorbance excited at 525 
nm. 
 
 
Figure 70. Emission spectra of compounds 11, 19 and 25   with equal absorbance excited at 585 
nm. 
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 For compound 25 carries two different types of donors, namely BODIPY 
and monostyryl-BODIPY. Emission spectra with equally absorbing compounds 
(Figure 63) show that both emissions at 539 nm and 606 nm decrease 
substantially upon excitation at 525 nm and 585 nm respectively, due to energy 
transfer (Figure 69 and 70). Energy transfer efficiencies were determined to be 
90% from the BODIPY terminal units to either mono or distyryl-BODIPYs and 
93% from monostyryl-BODIPY to the core. Interestingly, with this dendrimer, 
emission at 672 nm is achieved even when the compound is excited at 150 nm 
below, at 525 nm. This enables spanning of a large region of the visible 
spectrum with a single molecule and to funnel energy in certain part, which is 
gorgeous. More strikingly, emission intensity at 672 nm is larger when the 
compound is excited at 525 nm compared to excitations at 585 nm and 645 nm 
as shown in Figure 71.  
 
 
Figure 71. Comparison of emission of 25 excited at 525 nm (orange), 585 nm (red) and 645 nm 
(green). 
 
98 
 
 
Figure 72. Schematic representations and FRET efficiencies of compounds 21, 23, 24 and 25. 
 
 To sum up, direction of energy transfer and FRET efficiencies for 
compounds 21, 23, 24 and 25 are illustrated in Figure 72. Core distyryl-
BODIPY is shown in color green, monostyryl-BODIPY that surrounds core is 
shown in red and finally outer BODIPY units are in orange. To generalize, 
FRET efficiency varies from 90% (compound 25) to 97% (compound 21). 
Maximum energy transfer is achieved from BODIPY to monostyryl-BODIPY 
with FRET efficiency of 97%. Considering the distance dependence of FRET 
rate constant and efficiency, using shorter linkers between chromophores may 
increase the efficiencies even more. Here, 6-carbon flexible linkers were used.  
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 In this research, highly efficient energy harvesting with BODIPY-based 
dendrimeric antenna is presented. This antenna shows cascade property by 
channeling energy to the core and enhancing core fluorescence emission. This 
enhancement is larger when the dendrimer was excited at primary donor, 
namely terminal BODIPY units.This system can be used in a number of 
applications such as to label proteins, to produce panchromatic dyes for dye-
sensitized solar cells, for signal amplification and frequency conversion 
purposes or in construction of a variety of optoelectronic devices. 
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CHAPTER 4 
 
CONCLUSION 
 
In this research novel, water soluble BODIPY-based photodynamic 
therapy reagent was synthesized and characterized. SWNTs were non-covalently 
functionalized with these photosensitizers and suscessfull photodynamic ability 
was observed. In addition, four different BODIPY-based dendrimers were 
synthesized and energy transfer efficiencies were examined. 
 Compound 1 is designed to be used in PDT. Through rational synthesis, 
PDT requirements such as water solubility, enhanced intersystem crossing is 
provided using PEG and iodines respectively. SWNTs are used as potential 
delivery system for PS and non-covalent functionalization was achieved through 
pyrene-SWNT pi−pi interactions. Attachment was characterized well using 
quenching of pyrene emission and AFM, TEM electron micrographs. Singlet 
oxygen generation experiments show that compound 1 is an efficient singlet 
oxygen generator in nanomolar concentrations, even when it is stacked on 
SWNT. In the second part, four different dendrimers each carrying different 
number of donors and acceptors were synthesized and spectral and fluorescence 
decay analyses were done. More than 90% energy transfer from donors to core 
acceptor was observed through either using decrease in lifetime of donors or 
from quantum yields. Cascade-like energy transfer system result in enhanced 
emission at the core even the system was excited at 150 nm below elucidating 
the efficiency of light harvesting.  
In conclusion, we have demonstrated that SWNTs can be used in the 
delivery of PS for the use in PDT while preserving their singlet oxygen 
generation capability and highly efficient FRET in multichromatic cascade-type 
BODIPY dendrimers were reviealed.  
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APPENDIX A 
 
 NMR SPECTRA 
 
Figure 73. 1H  NMR spectrum of compound 3. 
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Figure 74. 13C  NMR spectrum of compound 3 
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Figure 75. 1H  NMR spectrum of compound 4 
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Figure 76. 13C  NMR spectrum of compound 4 
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Figure 77. 1H  NMR spectrum of compound 5 
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Figure 78. 13C  NMR spectrum of compound 5 
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Figure 79. 1H  NMR spectrum of compound 6 
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Figure 80. 13C  NMR spectrum of compound 6 
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Figure 81. 1H  NMR spectrum of compound 7 
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Figure 82. 13C  NMR spectrum of compound 7   
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Figure 83. 1H NMR spectrum of compound 8  
 
 
122 
 
 
 
Figure 84. 13C NMR spectrum of compound 8     
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Figure 85. 1H NMR spectrum of compound 1 
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     Figure 86. 13C NMR spectrum of compound 1 
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Figure 87. 1H  NMR spectrum of compound 9. 
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Figure 88. 13C NMR spectrum of compound 9. 
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Figure 89. 1H  NMR spectrum of compound 10. 
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Figure 90. 13C  NMR spectrum of compound 10. 
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Figure 91. 1H  NMR spectrum of compound 11. 
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Figure 92. 13C  NMR spectrum of compound 11. 
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Figure 93. 1H  NMR spectrum of compound 13. 
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Figure 94. 13C  NMR spectrum of compound 13. 
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Figure 95. 1H  NMR spectrum of compound 14. 
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Figure 96. 13C  NMR spectrum of compound 14. 
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Figure 97. 1H  NMR spectrum of compound 15. 
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Figure 98. 13C NMR spectrum of compound 15. 
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Figure 99. 1H NMR spectrum of compound 16. 
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Figure 100. 13C NMR spectrum of compound 16. 
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Figure 101.1H NMR spectrum of.compound 17. 
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Figure 102. 13C NMR spectrum of compound 17. 
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Figure 103. 1H NMR spectrum of compound 18. 
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Figure 104. 13C NMR spectrum of compound 18. 
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Figure 105. 1H NMR spectrum of compound 19. 
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Figure 106. 13C NMR spectrum of compound 19. 
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Figure 107. 1H NMR spectrum of compound 20.  
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Figure 108. 13C NMR spectrum of compound 20. 
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Figure 109. 1H NMR spectrum of compound 21.  
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Figure 110. 13C NMR spectrum of compound 21. 
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Figure 111.1H NMR spectrum of compound 22. 
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Figure 112. 1H NMR spectrum of compound 23. 
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Figure 113. 13C NMR spectrum of compound 23. 
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Figure 114. 1H NMR spectrum of compound 24. 
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Figure 115. 1H NMR spectrum of compound 25. 
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Figure 116. ESI-HRMS of compound 3.  
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Figure 117. ESI-HRMS of compound 4.  
 
 
 
 
Figure 118 ESI-HRMS of compound 5 
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Figure 119. ESI-HRMS of compound 6 
 
 
 
Figure 120. ESI-HRMS of compound 7. 
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Figure 121. MALDI-MS of compound 8 
 
 
 
 
 
 
Figure 122. MALDI-MS of compound 1 
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Figure 123. ESI-HRMS of compound 11.  
 
 
 
 
 
 
 
 
Figure 124. ESI-HRMS of compound 14.  
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Figure 125. ESI-HRMS of compound 15.  
 
 
 
 
 
 
 
 
 
 
Figure 126. ESI-HRMS of compound 17.  
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Figure 127. ESI-HRMS of compound 18 
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Figure 128. ESI-HRMS of compound 19. 
 
 
 
 
Figure 129. ESI-HRMS of compound 20. 
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Figure 130. MALDI-MS of compound 21. 
 
 
 
 
 
 
Figure 131. MALDI-MS of compound 23. 
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Figure 132. MALDI-MS of compound 24. 
 
 
 
 
 
 
 
Figure 133. MALDI-MS of compound 25. 
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FLUORESCENCE DECAY SPECTRA 
 
 
 
 
 
 
 
 
 
Figure 134. Fluorescence decay spectrum of compound 15. 
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Figure 135. Fluorescence decay spectrum of compound 19. 
 
 
 
 
 
 
 
Figure 136. Fluorescence decay spectrum of compound 20.  
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Figure 137. Fluorescence decay spectrum of compound 21. 
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Figure 138. Fluorescence decay spectrum of compound 25, emission at 545 nm. 
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Figure 139. Fluorescence decay spectrum of compound 25, emission at 675 nm.  
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